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Abstract 
Abstract 
Neoparamoeba spp. is a marine amphizoic protozoan parasite which infects the 
gills of marine cultured Atlantic salmon, Salmo salar, worldwide causing amoebic 
gill disease (AGD). Amoebic gill disease is a significant health issue affecting the 
production of sea-caged Atlantic salmon in Australia with farms experiencing 
outbreaks regularly throughout the year. It accounts for 10-20% of the gross value 
of production due not only to the cost of treating and managing the disease, but also 
to loss of fish condition, increased feed conversion ratio (FCR), lost growth and 
sometimes mortalities. The current mitigation strategy for AGD is the 
administration of a freshwater bath to affected sea-caged fish. However, this 
method is becoming less effective with an apparent increase in bathing frequency 
over the past few years. The increase in baths has fuelled a rise in already high 
production costs to the Australian Atlantic salmon industry to approximately 20% 
annually. This thesis aims to identify an improved method of treatment for AGD 
either through development of a stand alone in-feed treatment or an in-feed 
treatment used in conjunction with the current freshwater treatment strategy. 
This thesis investigates in vitro and in vivo effects of bithionol and bithionol 
sulphoxide on both Neoparamoeba spp. and Atlantic salmon. Initially, toxicity to 
Neoparamoeba spp. was examined in vitro using isolated gill amoeba and exposing 
them to seawater, freshwater, alumina (10 mg 1: 1 ), bithionol and bithionol 
sulphoxide at 10, 5, 1, 0.5 and 0.1 mg L. The assays were observed for 72 h with 
viable amoeba counts using trypan blue exclusion conducted at 0, 24, 48 and 72 h. 
Both bithionol and bithionol sulphoxide were toxic to Neoparamoeba spp. in vitro 
Abstract 
at all concentrations examined. A similar toxicity to freshwater water was observed 
with bithionol and bithionol sulphoxide at 10 and 5 mg L-1 following a 72 h 
treatment. However, freshwater was the most effective with only 6% viable 
amoebae seen after 24 h and no viable amoeba observed a further 24 h later. 
Once identified as toxic to Neoparamoeba spp. in vitro, an assessment of the 
toxicity of bithionol to Atlantic salmon and the efficacy as an AGD treatment was 
evaluated. This was conducted via a bath treatment to Atlantic salmon and rainbow 
trout, Oncorhynchus mykiss, held in either fresh or seawater using concentrations 
between 1 and 35 mg L-1 to examine toxicity. To examine efficacy, a bath treatment 
of AGD-affected Atlantic salmon and rainbow trout at 1 to 25 mg L -1 was also 
evaluated. To examine toxicity, fish were bathed for 1, 3 and 6 h in bithionol, an 
anti-protozoal at 0, 1, 5, 10, 25 and 35 mg L -1 , with toxicity determined by time to 
morbidity and histological examination of internal organs. Efficacy was examined 
by bathing AGD-affected Atlantic salmon and rainbow trout for I h at bithionol 
concentrations of 1 to 25 mg L -1 . Efficacy was determined by examining gill 
amoeba counts and identifying percent lesioned gill filaments at I and 24 h after 
bath exposure to bithionol. Only bithionol at 1 mg L-1 was considered non-toxic 
with no signs of morbidity. Bithionol appeared to be more toxic in seawater than 
freshwater, exhibiting a higher rate of morbidity, and had no acute effects on gill 
Na+/K+ ATPase and succinic dehydrogenase, or plasma osmolality and chloride 
concentration. Bithionol reduced the percentage of lesioned gill filaments to the 
same level as freshwater. 
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Abstract 
Bithionol was examined as an in-feed treatment for AGD with and without the 
administration of a freshwater bath. Bithionol when fed as a two week prophylactic 
or therapeutic treatment at 25 mg kg' feed delayed the onset of AGD pathology and 
reduced the percent lesioned gill filaments. Administration of a 3 h freshwater bath 
at 28 days post-exposure significantly reduced amoebae numbers to a similar level 
across all treatments; in contrast gross gill score and percent lesioned filaments 
were reduced proportionally. Hence, the control was significantly higher than both 
bithionol treatments. Following the freshwater bath, clinical signs of AGD recurred 
at a similar level across all treatments although controls clinical signs were 
significantly higher than the bithionol treatments to begin with. Palatability was not 
a problem with mean feed intake of bithionol over the trial duration higher 
compared to both the oil and plain controls. 
This thesis has identified that bithionol at 25 mg kg -I feed, when fed as a two 
week prophylactic or a therapeutic treatment, delayed and reduced the intensity of 
AGD pathology. Such findings as the identification of bithionol as a possible in-
feed treatment for AGD and its effectiveness against numerous other parasites 
suggests that bithionol could be worth examining in other aquatic animal diseases. 
Furthermore, bithionol warrants further investigation as a potential in-feed 
treatment for AGD in Atlantic salmon especially in regards to a combination 
therapy with the current freshwater mitigation. 
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CHAPTER 1 
GENERAL INTRODUCTION 
Chapter One 	 General Introduction 
1 General Introduction 
1.1 The impact of amoebic gill disease (AGO) on Atlantic salmon, Salmo 
salar, in Australia 
Amoebic gill disease is a significant health issue affecting the production of sea-
caged salmon in Tasmania, Australia, with farms experiencing regular outbreaks 
throughout the year (Clark and Nowak, 1999; Munday et al., 2001; Nowak et al., 
2002) accounting for 10-20% of the gross value of production (Munday et al., 
2001). However, AGD outbreaks are generally most severe during the summer 
months; previous studies have shown that salinity and temperature are significant 
environmental factors influencing the outbreaks of AGD (Clark and Nowak, 1999; 
Douglas-Helders etal., 2001b; Adams and Nowak, 2003). Other factors that are 
thought to influence AGD outbreaks include rainfall (Munday etal., 1993; Clark 
and Nowak, 1999; Nowak, 2001), dissolved oxygen (Clark and Nowak, 1999), 
biofouling on cages (Tan etal., 2002), husbandry techniques (Clark and Nowak, 
1999), removal of mortalities (Douglas-Helders et al., 2000), the general health 
status of the fish (Nowak, 2001) and possibly bacterial gill populations (Bowman 
and Nowak, 2004; Embar-Gopinath etal., 2005). 
The increase gross production costs mentioned above is due not only to the cost of 
treating and managing the disease, but also to loss of fish condition, increased feed 
conversion ratio (FCR) and lost growth attributed to an increase in standard 
metabolic rate (Leef et al., 2007a). If left untreated fish mortalities can reach over 
50% (Munday et al., 1990) and furthermore pose a greater financial loss to the 
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industry. As well as mortalities, reduced growth can also be an issue taking a longer 
time to reach market size (Rodger and McArdle, 1996; Dykova etal., 1998). 
1.2 The etiology of amoebic gill disease 
1.2.1 	The agents associated with amoebic gill disease 
The presumptive causative agent of AGD is a marine amphizoic protozoan 
parasite, identified as Paramoeba pemaquidensis (Page, 1970) and then reclassified 
to Neoparamoeba pemaquidensis (Page, 1987). More recently other amoeba 
species, N. branchiphila and N aestuarina, were cultured from AGD affected fish, 
but it was not known if one or all of these species were the aetiological agents of 
AGD (Dykoyd etal., 2005). Subsequently, a new amoeba species designated 
Neoparamoeba perurans n. sp. has been identified as the predominate aetiological 
agent of AGD affecting Atlantic salmon, Salmo salar, culture in Tasmania 
invalidating previous classifications (Young et al., 2007). 
Neoparamoeba (Page, 1987) are small, naked and lobose amoebae that form 
dactylopodiate subpseudopodia in their locomotive state and belong to the family 
Vexilliferidae. Some defining characteristics enabling classification of this genus 
include the fact that forms lack the well organised cell-surface structures of other 
vexilliferids including surface scales and hexagonal glycostyles. They also possess 
a nucleus plus one or more `parasomes'. These `parasomes' are described as 
Perkinsiella amoebae like organisms (PLOs) and are eukaryotic endosymbionts, 
closely related to the kinetoplastid khthyobodo (Dykova et al., 2003). 
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Neoparamoeba spp. is not confined to Australian waters, with AGD outbreaks 
worldwide including Ireland, Spain, New Zealand, USA (Washington State and 
California), Chile, and more recently Norway (reviewed by Munday et al., 2001; 
Nowak etal., 2002; Steinum etal., 2008). Amoebic gill disease has also been found 
to affect a number of other species including Atlantic salmon (Kent etal., 1988; 
Munday etal., 1990), rainbow trout, Oncorhynchus mykiss, (Munday etal., 1990), 
brown trout, S. Trutta, (Munday etal., 2001), coho salmon, 0. Kisutch, (Kent etal., 
1988), chinook salmon, 0. Tshawytscha, (Kent et al., 1988), turbot, Scophthalmus 
maximus, sharpsnout seabream, Diplodus puntazzo, and European sea bass, 
Dicentrarchus labrax, (Dykova et al., 2000; Dykova and Novoa, 2001). Atlantic 
salmon are reported to be the most susceptible of cultured species (Munday et al., 
2001), but interestingly AGD has not been reported in other wild fish species 
including red cod, Pseudophycis bachus, sand flathead, Platycephalus bassensis, 
and jack mackerel, Trachurus declivus, even when present around farms with 
severely affected salmon (Nowak et al., 2004). 
Throughout this thesis, the causative agent of AGD is referred to as 
Neoparamoeba spp. Furthermore, this work was conducted prior to the discovery 
of N. perurans and Neoparamoeba spp. is used in reference to the aetiological agent 
of AGD. However, irrespective of the term used to describe the organism, it is 
referring to the isolated gill amoebae and hence the species of Neoparamoeba 
which are the aetiological agents of AGD. 
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1.2.2 	Morphology and identification 
When freshly isolated from the gills of infected fish, Neoparamoeba spp. appear 
in their free floating form as spherical and possess multiple pseudopodia (Kent et 
al., 1988; Munday etal., 1990; Rodger and McArdle, 1996; Dykova etal., 1998). 
However, a more lobose form is assumed when Neoparamoeba spp. are attached to 
a substrate with the nucleus and "parasome(s)" generally visible (Fig 1.2-1). In 
histology sections using either wax or resin, both the nucleus and "parasome(s)" are 
visible and the trophozoites often appear highly vacuolated (Roubal et al., 1989; 
Munday et al., 1990; Dykova etal., 1995). While morphological characteristics 
distinguish Neoparamoeba from other vexilliferids, attempts to distinguish 
members of the genus Neoparamoeba using morphological characteristics alone 
have been unsuccessful (Dykova et al., 2000; Dykova et al., 2005). 
-5- 
Chapter One 
	 General Introduction 
Fig 1.2-1. Attached trophozoites of Neoparamoeba pemaquidensis from a 
sediment isolate showing pseudopodia (fine arrow), nucleus (unfilled arrow), and 
"parasome" (filled arrow) (plate courtesy of Dr Bret Robinson) Bar = 20pm. 
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Detection of Neoparamoeba spp. can be achieved using both pathogen specific 
and non-specific tests with samples being obtained either lethally or non-lethally to 
the fish. A wet mount preparation, whereby gill mucus is smeared onto a glass slide, 
dried, stained and examined microscopically, is based primarily on the morphology 
of the pathogen. Histology is reliable but the obtaining of histology samples is lethal 
to the fish and once again reliant upon morphology. Specific stains, such as indirect 
fluorescent antibody test (IFAT) (Howard and Carson, 1993), immuno-
cytochemistry (Zilberg and Munday, 2000; Howard, 2001) and immune-dot blot 
(Douglas-Helders etal., 2001a), can also be used on histological sections and gill 
smears, although not particularly reliable for assessing infections on some farms or 
assessing treatment efficacy (Harris et al., 2004; Harris et al., 2005). Immunological 
detection of Neoparamoeba using anti-N. pemaquidensis antiserum was reported 
successful in identifying different Neoparamoeba spp. (Douglas-Helders et al., 
2001a). However, the anti-N pemaquidensis antiserum was later shown to bind 
non-specifically to other marine amoebae (Morrison etal., 2005). Recently, N. 
branchiphila was characterised using a combination of morphological and 
molecular phylogenetic analyses inferred from 18S rRNA gene sequences (Fiala 
and Dykova, 2003; Dykova et al., 2005) and was clearly differentiated from N. 
pemaquidensis and N. aestuarina. Furthermore, this resolved inter-specific 
relationships within the Neoparamoeba group (Fiala and Dykova, 2003; Dykova et 
al., 2005). Hence, species-specific diagnostic tools were developed, based upon 18S 
rRNA gene amplification by polymerase chain reaction (PCR) to study disease 
aetiology where Neop" aramoeba spp. were the presumptive pathogens (Elliott et al., 
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2001; Fiala and Dykova, 2003; Wong etal., 2004; Dykova etal., 2005; Mullen et 
• at, 2005; Young etal., 2007). 
1.3 Pathology and pathophysiology of amoebic gill disease in Atlantic salmon 
Amoebic gill disease is characterised clinically or macroscopically by the 
presence of gross gill lesions which are characterised by focal or multifocal, raised 
white mucoid patches, profuse mucus production and mucous cell proliferation 
(Clark and Nowak, 1999; Adams and Nowak, 2001; Roberts and Powell, 2003b). 
Gross examination of gills for the presence of white patches is routinely used by the 
Ta.smanian Atlantic salmon industry for gross tentative diagnosis of AGD and 
determination of treatment times. Other clinical signs reported for AGD include 
lethargy, loss of appetite and respiratory distress manifested as rising to the water 
surface and an increased ventilation frequency; however, due to routine farm 
monitoring and early treatment, disease rarely progresses to the point at which such 
behaviour is elicited (Munday etal., 1990; Munday etal., 2001). The prominent 
microscopic feature of AGD is multi-focal hyperplasia of the lamellar epithelium 
which, in turn, results in the , ftsion of secondary lamellae and formation of 
interlamellar vesicles, which coincides with a reduction in chloride cell number and 
an increase in mucous cells (Dykova etal., 1995; Powell etal., 2001; Adams and 
Nowak, 2003; Roberts and Powell, 2003b). Typically AGD lesions are associated 
with Neoparamoeba spp. present within the vicinity of the hyperplastic tissue 
(Nowak and Munday, 1994). As the disease progresses, the hyperplastic tissue 
along with associated amoeba are sloughed off, which has been thought to be a 
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possible 'self-cleaning' action important for the recovery from the disease (Munday 
etal., 2001). 
Physiologically, Munday et al. (1990) reported elevated blood sodium levels in 
Atlantic salmon severely affected with AGD; however, Powell et al. (2001) 
reported that there were no clinical observations regarding this. Fish affected by 
AGD are known to have lower blood oxygen partial pressure (P02) despite the fact 
that oxygen uptake rates are not affected under normoxic conditions in clinically 
affected fish (Powell etal., 2000). Elevated blood carbon dioxide (tensions) (PCO2) 
are also seen in AGD-affected Atlantic salmon resulting in respiratory acidosis 
(Powell etal., 2000; Leef et al., 2005b). It has been suggested that this respiratory 
acidosis exhibited in AGD-affected fish maybe a result of the presence of AGD 
lesions and/or an increase in branchial mucous secretion which in turn leads to a 
reduced gill surface area and diffusive conductance (Powell et al., 2000). Even 
though it has been shown that AGD-affected fish are acidotic, the presence of AGD 
did not appear to contribute to respiratory failure when AGD-affected fish were 
exposed to hypoxic condition at approximately 25% saturation. Furthermore, 
suggesting that although physiological mechanisms including increased blood flow 
and perfusion within the gill, AGD-affected fish were able to maintain oxygen 
transport (Powell et al., 2000). 
Amoebic gill disease is associated with a chronic vascular hypertension as well as 
compensatory cardiac remodelling. Whilst examining the cardiovascular effects of 
AGD, Powell et al. (2002b) hypothesised that in cases of chronic AGD, a 
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compensatory response for high ventral (afterload) and dorsal (preload) aortic 
pressure (as seen by Powell et al. (2002a)) may be to promote morphological 
changes in both ventricle length and the thickening of ventricular compact muscle. 
Atlantic salmon affected with AGD have been shown to have high systemic 
resistance and lowered cardiac output when compared to naïve counterparts, a 
characteristic of Atlantic salmon not seen in either rainbow or brown trout (Leef et 
al., 2005a). There is evidence to suggest that AGD may possibly be associated with 
cardiovascular dysfunction (Powell etal., 2002a; Powell et al., 2002b); this was 
supported by Leef et al. (2005a; 2007b). 
When affected with AGD, the critical swimming speed and subsequent recovery 
of Atlantic salmon is significantly affected. Furthermore, following a freshwater 
bath the swimming performance was found to increase with the suggestion that this 
post-bath increase observed is due to the removal of amoeba and hyperplastic gill 
tissue (M. Jones pers. comm.). The excess post-exercise oxygen consumption 
doubled in AGD-affected fish compared to uninfected controls, hence infected fish 
need longer to repay their oxygen debt and recover oxygen consumption rates to 
routine levels (M. Jones pers. comm.). This supports earlier observations of Powell 
et al. (2002a) where freshwater bathing also led to a decrease in dorsal aortic 
pressure in clinically affected fish. Oxygen consumptions rates have been used 
indirectly to measure metabolic rate in AGD-affected Atlantic salmon. It was 
reported that both routine metabolic rate and metabolic scope are significantly 
affected, with the magnitude of effect linked to the severity of AGD. Suggesting 
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that AGD infection does have a significant metabolic cost associated however, only 
at high infection levels (M. Jones pers. comm.). 
1.4 Freshwater therapy for amoebic gill disease 
1.4.1 	History 
The mitigation of AGD in Tasmania, Australia, is mostly due to freshwater 
bathing for 2-4 h, which was first recommended by Foster and Percival (1988). On 
the farm, fish are routinely sampled non-lethally to examine the presentation of 
raised white mucoid patches, and given a gill score based upon the presence of 
patches, mucus and colouration of the gills (Table 1.4-1) (Powell etal., 2001; Fisk 
etal., 2002). Following gross diagnosis, fish are bathed for 2-4 h if required 
(Parsons etal., 2001a). It is suspected that a combination of osmotic challenge to 
amoeba, removal of seawater stable gill mucus and the dissolution of gill lesions 
contributes to treatment success (Munday etal., 2001; Parsons et al., 2001a; 
Roberts and Powell, 2003b; Adams and Nowak, 2004a). However, the efficacy is 
variable and has notably become increasingly less effective (Parsons et al., 2001a; 
Powell and Clark, 2003), possibly due to differing water chemistries (Parsons et al., 
2001b). This was supported both in vitro and in vivo with survival of gill amoeba 
reported as lower in soft freshwater (low total hardness) compared to hard 
freshwater (high total hardness) (Powell and Clark, 2003; Roberts and Powell, 
2003a). When freshwater bathing was first introduced in the late 1980s, two to three 
baths Were sufficient in providing alleviation from AGD during the marine 
production cycle (Foster and Percival, 1988; Clark and Nowak, 1999). Presently, 
.however, fish may require up to ten baths in the same period to achieve sufficient 
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alleviation of AGD (Mitchell, 2001). It has been demonstrated that there was 
survival of amoebae within mucous samples following bathing and amoebae have 
been observed within inter-lamellar Vesicles suggesting a potential source of 
recurrent infection (Parsons etal., 2001a). However, this was later refuted by 
Adams and Nowak (2001) identifying the vesicles as closed structures containing 
dead or dying amoeba. Furthermore, Clark et al. (2003) reported gill associated 
amoeba numbers return to pre-bath levels ten days following treatment. 
Table 1.4-1. Huon Aquaculture Company Dover, Australia method for AGD 
gross gill lesion scoring scheme. 
Infection level Score Gross signs 
Clear 	0 	Gills appear clean, healthy and red in colour 
Very Light 	1 	1 mucoid patch, light mucus accumulations 
Light 	2 	2-3 mucoid patches, some paling colour 
Medium 	3 	Established thickened mucoid patches and mucus 
Heavy 4 	> 3 mucoid patches or a single large patch resulting from 
patch accumulation 
1.4.2 	Effects of freshwater bathing 
The two major events that occur during commercial freshwater bath treatment 
include: 1) removal of attached and/or associated trophozoites from the gills, and 2) 
the osmotic killing of amoebae flushed from the gills to the treatment medium. It 
was hypothesised that freshwater sloughs mucus and, to some degree, the 
epithelium from the gills, thus removing amoebae (Munday etal., 2001). Nowak et 
al. (2007) hypothesised that it is likely that amoebae "let go" of a given substrate as 
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trophozoites succumb rapidly to the osmotic effects of freshwater through swelling 
or "balling up" and disruption to cytoplasmic organelles. 
A number of studies have shown that freshwater bathing has therapeutic effects of 
promoting repair of the amoeba-induced damage to the gills via the sloughing off of 
hyperplastic tissue, reducing the number of gill lesions (Munday et al., 2001; 
Roberts and Powell, 2003a) and the hydration and removal of mucus from the gills 
(Roberts and Powell, 2003b). The ability of a bath to flush amoebae from the gills 
into the surrounding treatment medium is most likely to be dependent upon many 
factors such as: water chemistry, bath duration, velocity of the water and the 
severity of infection, as well as others not yet considered. The fact that re-infection 
under experimental conditions can occur after a 3 h freshwater bath treatment 
without further addition of infective material post-bath suggests amoebae are able to 
survive within the gill environment during treatment and reproduce disease 
following return to full salinity (Gross et al., 2004). 
During a short-term exposure to freshwater, as is experienced in commercial 
freshwater bathing, there appear to be no adverse physiological effects on AGD-
affected Atlantic salmon and no effects on plasma ions or branchial chloride cells 
(Powell etal., 2001). However, the number of branchial mucous cells increased 
coinciding with a change in their histochemical staining and the gill mitochondrial 
marker succinic dehydrogenase (SDH) activity significantly decreased, suggesting 
that freshwater bathing has the potential to reduce hyper-ionregulatory capacity of 
AGD-affected marine Atlantic salmon (Powell et al., 2001). Thus, it was concluded 
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that when used as a treatment for AGD, a minimum 2 h freshwater bath poses little 
side effects, neither positive or negative, with regard to the physiological status of 
the salmon (Powell et al., 2001) 
1.5 Alternative treatments for amoebic gill disease 
1.5.1 	Chemotherapeutant drugs tested to date 
A large variety of antimicrobials, disinfectants and detergents have been 
examined both in vitro on isolated gill amoebae and in vivo as both bath and feed 
additives for AGD mitigation. The chemicals that have been examined in vitro for 
amoebicidal or amoebistatic properties include quinacrine, pyrimethamine, 
levamisole, quinoline, hydroxyquinoline, narasin, napthoquinone, hydrogen 
peroxide, chlorine dioxide, chloramine-T, L-cysteine ethyl ester, CitroxTM, 
amprolium (Amprolium200Tm), toltrazuril (BaycoxTm ), bithionol, albendazole 
(AlbenTm), caprylic acid, monensin, salinomycin (Bio-CoxTm), lasalocid acid 
(BovatecTm), maduramycin (CygroTm), metronidazole, and bronopol (Pyceze TM) 
(Table 1.5-1) (Alexander, 1991; Howard and Carson, 1993; Powell etal., 2003; 
Powell and Clark, 2003; 2004; Powell etal., 2005; Powell.et al., 2008). Compounds 
examined as feed and bath chemical additives in vivo have generally been identified 
as ineffective in relieving clinical signs of AGD at the concentrations used (Table 
1.5-1). Narasin when fed at 50-60 mg kg -I body weight (BW) for 7 days was found 
to reduce AGD gill lesions; however, palatability problems were identified and 
trials were discontinued (Cameron, 1992). Levamisole has been previously 
examined with varying results; it was found to be ineffective when fed every third 
day for 15 days at 15 mg kg -I BW (Cameron, 1992). In contrast, 1.25 to 5 ppm 
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levamisole in freshwater for 2-3 h was reported effective as it significantly 
augmented the efficacy of the freshwater bath (Findlay et al., 2000). Furthermore, 
when levamisole was provided as a bath supplement under field conditions, Clark 
and Nowak (1999) were unable to detect a beneficial effect. 
Another chemotherapeutant that has been previously examined with mixed results 
is chloramine-T. Although listed as ineffective by Munday et al. (2001), subsequent 
studies using chlorarnine-T as a bath additive have produced some promising yet 
varied results. Chloramine-T has been found to significantly reduce gill amoeba 
numbers when added to freshwater during a commercial bathing trial on one farm 
but not on another and its efficacy depends on factors such as water chemistry 
(Powell and Clark, 2004). Recently, chloramine-T as an additive to seawater has 
been shown to be an effective AGD treatment under experimental conditions 
(Harris etal., 2004; Harris et al., 2005) although it was found to be niore acutely 
toxic to Atlantic salmon in seawater as opposed to freshwater (Powell and Harris, 
2004). 
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Table 1.5-1. Compounds examined ds possible treatmzents for amoebic gill disease. 
Compound Type of drug Type of test Type of treatment Relative efficacy Relative 
toxicity* 
Referencet 
Amprolium Antiprotozoal In vitro N/A 1 1 
Toltiazuril Antiprotozo al In vitro N/A 1 1 
Albendazole Antiprotozoal In vitro N/A 1 1 
Caprylic acid Anti-fungal In vitro N/A 1 1 
Bronopol Biocide In vitro N/A 1 2 
Formalin Biocide In vitro N/A 1 2 
Monensin Ionophore In vitro N/A 1 2 
Salinomycin Ionophore In vitro N/A 2 3 
In vivo In-feed Low 1 3 
Lasalocid acid Ionophore In vitro N/A 1 3 
In vivo In-feed Low 1 3 
Maduramycin Ionophore In vitro N/A 1 3 
Metronidazole Metabolic inhibitor In vitro N/A 1 2 
Bithionol Antiprotozoal In vivo Bath Moderate 2 4 
Bithionol Antiprotozo al In vivo In-feed Moderate 1 5 
Chloramine-T Disinfectant In vivo Bath Moderate 1 6 and 7 
Chlorine Dioxide Disinfectant In vivo Bath Moderate Variable 7 
Hydrogen Peroxide Disinfectant In vivo Bath Moderate 2 7 
Levami sole Immuno stimul ant In vivo Bath Moderate 1 8 and 9 
L-cysteine ethyl ester Mucolytic In vivo In-feed Moderate N/A 10 
* In vitro toxicity to amoebae, in vivo toxicity to fish 1 = low to moderate toxicity; 2 = high toxicity 
I 1 = (Powell etal., 2003); 2 = (Powell et al., 2005); 3 = (Powell etal., 2008); 4 = (Florent etal., 2007a); 5 = (Florent etal., 2007b); 6 = (Harris etal., 
2004); 7 = (Powell and Clark, 2004); 8 = (Findlay et al., 2000); 9 = (Munday and Zilberg, 2003); 10 = (Roberts and Powell, 2005) 
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1.5.2 Bithionol and bithionol sulphoxide as novel treatments 
Bithionol is a white crystalline powder with a faint phenolic odour. It is insoluble 
in water and has the chemical structure as seen in Fig 1.5-1 (Enzie and Colglazier, 
1960; Yang and Lin, 1967). It was examined in 1960 as a treatment for 
paragonimiasis (lung fluke disease) in humans (Yang and Lin, 1967). In 1962, the 
discovery of bithionol sulphoxide (Fig 1.5-2) created another opportunity for 
disease treatment using a compound with allegedly less toxicity than bithionol 
(Yang and Lin, 1967). There appears to be some conflict in the literature with 
respect to bithionol and bithionol sulphoxide and how they relate to each other. 
Durbize et al. (2003) suggested that bithionol sulphoxide is a photoproduct of 
bithionol, whereas Mourot et al. (1987) hypothesised that in cows bithionol is a 
metabolite of bithionol sulphoxide via the reduction pathway. Similarly Meshi et al. 
(1970) found that in rats bithionol sulphoxide was oxidized to both bithionol 
sulphone and bithionol. Furthermore, they identified that the metabolic fate of these 
compounds was somewhat different. Bithionol sulphone was excreted mainly in 
urine as 3,5-dichioro-2-hydroxyphenylsulfonic acid, whereas bithionol was excreted 
mainly in bile as a glucuronide conjugate. 
CI CI 
CI CI 
Fig 1.5-1. Chemical structure of bithionol (2,2'-thiobis (4,6-dichlorophenol)). 
- 17- 
Chapter One 	 General Introduction 
C I CI 
CI CI 
Fig 1.5-2. Chemical structure of bithionol sulphoxide (Bis (2-hydroxy-3,5- 
dichlorophenyl) sulphoxide). 
Bithionol and bithionol sulphoxide have been used as a successful treatment for 
numerous human disease including paragonimiasis and fascioliasis (Yang and Lin, 
1967; Bacq etal., 1991). However, bithionol sulphoxide was found to have stronger 
anthelminthic activity than bithionol when examined in rats (Meshi etal., 1970). 
Bithionol and bithionol sulphoxide have also been examined as possible treatments 
for natural rumen fluke infections in cattle and tapeworm infections in cats, dogs, 
sheep and chickens (Enzie and Colglazier, 1960; Prasittirat etal., 1997). Bithionol 
was identified as toxic to medaka, Oryzias latipes, with a 96 h LC50 of 0.24 mg L -I , 
. whilst the cladoceran, Daphnia magna, and the rotifer, Brachionus calyciflorus, 
were both found to be susceptible to bithionol with 48 h and 24 h EC50 values of 0.3 
and 0.063 mg L -I respectively (Yoshimura and Endoh, 2005). 
Bithionol and bithionol sulphoxide have been examined with mixed results as 
both bath and oral treatments for numerous fish parasites including the flagellates, 
Ichthyobodo necator and Hexamita salmonis (Tojo etal., 1994a; Tojo and 
Santamarina, 1998a), the mongeneans, Microcotyle sebai tis (Kim and Choi, 1998), 
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Gyrodactylus spp. (Tojo et al., 1993) and Pseudodactylogyi-us spp. (Buchmann et 
al., 1992), and the protozoan, Trichodina jadranica (Madsen et al., 2000). 
Santamarina etal. (1991) observed limited toxicity and complete in vitro efficacy 
against Gyrodactylus sp. in rainbow trout at 12.5 mg L-1 , with a minimum 
20 mg L -1 reported as efficacious in vivo. Tojo etal. (1994b) stated that bithionol 
was efficacious in vivo against I. necator in rainbow trout at 25 mg L for a 3 h bath 
on two consecutive days; however, higher concentrations exhibited some mortality. 
Finally, Madsen etal. (2000) determined that bithionol at 0.1 mg L-1 was an 
effective treatment against trichodiniasis in European eels, Anguilla Anguilla; they 
found that bithionol had a relatively narrow therapeutic index. Bithionol has also 
been examined for its toxicity to Neoparamoeba spp. in vitro and was found to be 
amoebicidal at 1 and 10 mg L (Powell etal., 2003); however, when examined in 
vivo there were palatability issues (Powell unpublished). 
Bithionol at 40 g kg' feed was 'offered for 10 days at 2% BW per day to rainbow 
trout infected with Spironucleus salmonis formely known as (H. salmonis), 
Gyrodactylus sp. or I. necator and resulted in a reduction in parasite load. Bithionol 
eliminated approximately 80% of S. salmonis from rainbow trout while both 
Gyrodactylus sp.. and I. necator infections were reduced from a high to low 
intensity (Tojo and Santamarina, 1998a; b; c). Kim and Choi (1998) reported 
bithionol administered in feed at 100-200 mg kg ' 	significantly reduced the 
number of monogeneans, M. Sebastis, on the gills of cultured rock fish, Sebastes 
schlegeli, with a 20 day feeding duration being most effective. 
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1.6 
	
	Fish health management - the host, pathogen and environment 
interaction 
In common with mammalian and poultry farming, the aquaculture industry is 
subject to a . wide range of diseases; in fact Hedrick (1998) describes disease as an 
integral part of the existence of all animals. Some of these diseases can be 
controlled. However aquaculture involves intensive animal husbandry, maintaining 
large numbers of animals in a relatively limited space; it is these large numbers and 
limited space which has led to the exacerbation of diseases and an increased risk of 
disease outbreaks (Stoffregen et al., 1996). In contrast to mammalian therapeutics, 
the use of pharmaceutical substances, in particular antiparasitic drugs, in fishes is 
limited (Athanassopoulou etal., 2004). It is restricted to the use of anaesthetic 
agents and anti-infective agents for parasitic and microbial diseases (Burka et al., 
1997). 
Veterinarians, fish biologists, and ecologists differ significantly in their approach 
to infectious disease. Veterinary and human medicine believes that for a particular 
disease, Koch's postulates must be satisfied (Hill, 1965; Evans, 1976). However, in 
aquaculture the pathogenicity of infectious agents may be so severe that infected 
fishes die before they can be detected; consequently satisfying Koch's postulates 
may riot be possible. This does not, however, mean that their potential to cause 
disease should be ignored (Bakke and Harris, 1998). 
Disease covers a wide spectrum from acute mortality to benign syndromes; 
however, they all display a deviation from the normal structure Or function of the 
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host (Hedrick, 1998). Generally, diseases among cultured fish will result in poor 
growth and food conversion, which in turn increases production costs and interrupts 
production schedules (Hedrick, 1998). It is well known that fish diseases are not 
necessarily isolated events but are the end result of the relationship between 
pathogen, host and environment. A balanced relationship leads to good health and 
growth and a poor one to disease (Sanmartin Duran et al., 1991). The severity of the 
disease is dependent upon the interaction of numerous variables including, but not 
limited to, the host, the pathogen and the environment, labelled the "triad". This 
triad is described as three interlocking sections with disease occurring at the 
intersection (Martin etal., 1987; Thrusfield, 1995; Hedrick, 1998). 
Parasites often cause little damage to fish in their natural habitat; however, their 
presence in the aquaculture environment may result in disease, pathological 
changes, decreased condition and/or reduction in market value of the cultured 
species (Dickerson and Clark, 1998; Scholz, 1999; Kent, 2000; Jones, 2001; 
Buchmann and Lindenstrom, 2002). Mortality or morbidity of parasitised fish may 
occur due to osmoregulatory disturbances (Grimnes and Jakobsen, 1996), 
pathological changes (Dezfuli et al., 2002), immunosupression (Scharsack et al., 
2003), secondary infections (Mustafa etal., 2000) or stress (Bowers etal., 2000). 
For AGD the pathogen is N. perurans with susceptible hosts being certain fish 
species and the environment being the seawater that the fish are in. The interactions 
within and among the pathogen, host and environment are complex with many 
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variables involved (Thrusfield, 1995). The impact of this disease is dependent upon 
the interactions of these variables for the host, pathogen and environment. 
Host factors such as host species, fish size, population size and nutritional status 
are considered to be present constantly (Hedrick, 1998). Although AGD has been 
observed in numerous fish species, Atlantic salmon appear to be the most 
susceptible of cultured species (Munday etal., 2001). Furthermore, the increased 
stocking densities that are seen in aquaculture are also reported to contribute to an 
increased virulence of microorganisms (Murray and Peeler, 2005) 
The pathogen N. perurans has only recently been identified as the causative agent 
of AGD (Young et al., 2007) and as yet not a lot is known regarding this pathogen. 
Factors associated with the pathogen are known to include the delivery to the host, 
• duration of exposure, infectivity and number of pathogens which all in turn 
influence the severity of the disease (Hedrick, 1998; LaPatra, 1998). Douglas-
Helders etal. (2003) reported that N pemaquidensis remained infective for up to 14 
days with no host contact. Furthermore, transmission of AGD has been successful 
through co-habitation of affected salmon with naïve salmon (Zilberg and Munday, 
2000) as well as the exposure of fish to freshly harvested Neoparamoeba spp. from 
gills of fish known to have AGD (Zilberg etal., 2001). However, AGD has not 
been achieved when exposing fish to cultured Neoparamoeba spp. (Kent et al., 
1988; Howard etal., 1993). Since the discovery of N. perurans there is a need to 
investigate the culturing of the pathogen and the infectivity of this cultured 
pathogen. 
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Environment would probably be the least defined of the disease triad (Hedrick, 
1998) and environmental factors can often significantly contribute to disease 
outbreaks (Nowak, 1999). The two main environmental factors considered 
important to AGD outbreaks are salinity and temperature (Clark and Nowak, 1999; 
Munday et al., 2001). Other factors that are thought to influence AGD outbreaks 
include rainfall (Munday et al., 1993; Clark and Nowak, 1999; Nowak, 2001), 
dissolved oxygen (Clark and Nowak, 1999) and biofouling on cages (Tan et al., 
2002), although these are not considered as important as salinity and temperature. 
1.7 	Research objectives and specific aims 
The objective of this thesis was to investigate possible compounds for an oral 
treatment for AGD in Atlantic salmon. 
1.7.1 Specific aims 
Bithionol has previously been reported as amoebicidal at 1 and 10 mg U l 
over a period of six days and this study examined the toxicity of bithionol and 
bithionol sulphoxide to Neoparamoeba spp. at varying concentrations. It was 
hypothesised that bithionol would be amoebicidal at a wider range of concentrations 
than the 1 and 10 mg L -1 previously examined and that bithionol sulphoxide would 
exhibit similar amoebicidal tendency as that seen with bithionol. This was achieved 
through using the previously developed in vitro toxicity assay with 72 h duration 
and comparing bithionol and bithionol sulphoxide with seawater (positive control), 
alumina (particulate control) and the current freshwater mitigation (negative 
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control). The results were expected to provide compounds that were toxic in vitro to 
Neoparamoeba spp. that could then been examined in vivo for efficacy as an AGD 
treatment and serve as a basis for the research of subsequent chapters. 
It was hypothesised that bithionol would be efficacious as a bath treatment for 
AGD whilst being non-toxic to Atlantic salmon. The efficacy and toxicity of 
bithionol to both fresh and seawater AGD-affected and non-affected Atlantic 
salmon and rainbow trout; when administered as a maximum 3h bath treatment at 
varying concentrations in vivo was assessed in laboratory trials. This was to identify 
the possibility of using bithionol to either improve or replace the current 
commercial freshwater mitigation strategy. Pathology, blood plasma electrolytes, 
tissue SDH and Na±/K+ ATPase as well as time to morbidity were quantified to 
assess the toxicity of bithionol on Atlantic salmon and rainbow trout in fresh and 
seawater. 
Bithionol was assessed for its potential in alleviating AGD in Atlantic salmon. 
Bithionol was examined in vivo as an in-feed treatment to evaluate and describe the 
-1 efficacy and toxicity of bithionol when administered orally at 25 mg kg feed to 
Atlantic salmon 14 days prior to and 28 days post Neoparamoeba spp. exposure. 
Fish pathology, blood osmolality, and AGD parameters along with the feed intake 
of medicated feed pellets were quantified to assess the effects of bithionol as an oral 
treatment for AGD in Atlantic salmon. It was hypothesised that bithionol would be 
biotransfomed enabling its excretion across the gills which would in turn reduce the 
severity of AGD without any significant physiological consequences. The results 
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were expected to demOnstrate the potential of bithionol as either an alternative or 
combined mitigation strategy for AGD. 
Bithionol was assessed for its potential in alleviating AGD in Atlantic salmon in 
conjunction with the current freshwater bath mitigation. Prophylactic and 
- therapeutic oral administration of bithionol at 25 mg kg' feed was assessed prior to 
and post freshwater bath. Fish pathology, including gross gill score, percent 
lesioned filaments, lesion size, specific growth rate, feed intake, condition factor 
and feed conversion ratio, were quantified to assess the effects of treatment 
administration. It was hypothesised that prophylactic administration of bithionol 
would provide an enhanced treatment efficacy and that, when combined with a 
freshwater bath, bithionol would provide a cumulative effect of treatment. The 
results were expected to highlight the most effective strategy for the oral 
administration of bithionol and elucidate the effectiveness of combining oral 
bithionol therapy and freshwater bath administration. 
This chapter provides a summation of the main results and conclusions from all 
research chapters. The results and conclusions are discussed in terms of their 
relevance in light of the current literature regarding bithionol and its current uses as 
well as the development and use of treatments for AGD and other diseases such as 
sea lice. Consideration is given to future directions in regard to bithionol 
pharmacokinetics, environmental impacts, as well as combination therapy with 
freshwater and field trials. 
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2 In vitro efficacy of bithionol and bithionol sulphoxide to 
Neopartunoeba spp. the causative agent of amoebic gill disease 
(AGD) 
Renee L. Florent, Joy A. Becker, Mark D. Powell. 
2.1 	Abstract 
The objective of the study was to evaluate the in vitro toxicity of bithionol and 
bithionol sulphoxide to Neoparamoeba spp. Neoparamoeba spp. are the causative 
agent of amoebic gill disease (AGD) and the current treatment for AGD-affected 
Atlantic salmon, Salmo salar, involving bathing sea-caged fish in freshwater for a 
minimum of 3 h. This process is labour intensive and the number of baths needed 
appears to be increasing; hence there is an effort to identify alternative treatments. 
Toxicity to Neoparamoeba spp. was examined in vitro using amoeba isolated from 
the gills of Atlantic salmon and exposing them to freshwater, alumina (10 mg L -1 ), 
seawater, bithionol and bithionol sulphoxide at 0.1, 0.5, 1, 5 and 10 mg L i . The 
numbers of viable amoeba were counted using the trypan blue exclusion method at 
0, 24, 48 and 72 h. Both bithionol and bithionol sulphoxide demonstrated in vitro 
toxicity to Neoparamoeba spp. at all concentrations examined. A similar toxicity to 
freshwater was observed with both chemicals at concentrations >5 mg L -1 following 
a 72 h treatment. Freshwater was the most effective with only 6% viable amoebae 
seen after 24 h and no viable amoeba observed after 48 h. Bithionol and bithionol 
sulphoxide were toxic to Neoparamoeba spp. at concentrations ranging from 0.1 to 
10 mg L -1 over 72 h; however, freshwater still remained the most toxic with 
complete mortality seen at 48 h. 
- 27 - 
Chapter Two 	 Bithionol and bithionol sulphoxide efficacy in vitro 
2.2 	Introduction 
Bithionol, 2,2'-thiobis (4,6-dichlorophenol), and bithionol sulphoxide, bis (2- 
hydroxy-3,5-dichlorophenyl) sulphoxide, are halogenated anthelminthics that are 
known to uncouple electron transport (Rew, 1978). They act on the mitochondrial 
respiratory chain (Iglesias etal., 2002) and aid in the suppression of adenosine-5'- 
triphosphate (ATP) synthesis by uncoupling oxidative phosphorylation (Harder, 
2002). They are effective against trematode and cestocle infections in humans 
(Harder, 2002). Bithionol has been reported as effective for the treatment of 
metagonimiasis and paragonimiasis in humans and for killing the worms in vitro 
(Yokogawa etal., 1961a; Yokogawa etal., 1961b; Sawatari and HaMajima, 1967). 
Furthermore, bithionol is reported to kill the human parasite, Entamoeba histolytica, 
in vitro by inhibiting the endogenous and 2-propanol-supported respiration, but not 
the formation of ethanol in the parasite (Takeuchi et al., 1984). Bithionol and 
bithionol sulphoxide have been examined as possible treatments for natural rumen 
fluke infection in cattle and tapeworm infections in cats, dogs, sheep and chickens 
(Enzie and Colglazier, 1960; Prasittirat et al., 1997). 
Both bithionol and bithionol sulphoxide have been examined as treatments for 
numerous fish parasites and showed mixed results. Santamarina etal. (1991) 
observed limited toxicity and complete in vitro efficacy against Gyrodactylus sp. in 
rainbow trout at 12.5 mg L -1 , with a minimum 20 mg L -1 reported as efficacious in 
vivo. Tojo etal. (1994b) stated that bithionol was efficacious in vivo against 
khthyobodo necator in rainbow trout at 25 mg L -1 for a 3 h freshwater bath on two 
consecutive days; however, higher concentrations exhibited some mortality. Finally, 
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Madsen et al. (2000) determined that bithionol at 0.1 mg L -1 was an effective 
treatment against trichodiniasis in European eels, Anguilla anguilla, but found 
bithionol to have a relatively narrow therapeutic index. More recently, bithionol has 
displayed efficacy for the treatment of Neoparamoeba spp., the causative agent of 
amoebic gill disease (AGD) (Florent etal., 2007a; b). 
In Tasmania, amoebic gill disease is the primary disease affecting the production 
of Atlantic salmon. The presumptive causative agent of AGD is a marine amphizoic 
protozoan parasite. Page (1987) had previously classified the aetiological agent as 
Neoparamoeba pemaquidensis. More recently another amoeba species 
Neoparamoeba branchiphila was cultured from AGD affected fish, but it was not 
known if one or both of these species were the aetiological agents of AGD (Dykova 
et al., 2005). Furthermore, a new amoeba species designated Neoparamoeba 
perurans is believed to be the predominate aetiological agent of AGD affecting 
Atlantic salmon culture in Tasmania, invalidating previous classifications (Young et 
al., 2007). Neoparamoeba perurans has recently been reported in Norway, 
highlighting the cosmopolitan nature of this pathogen (Steinum etal., 2008) 
Commercial mitigation of AGD uses a freshwater bath for 3 h, which is said to 
remove the amoeba and promote improved gill health (Parsons et al., 2001a). 
However, the frequency of freshwater bathing has increased as it appears that each 
bath is proving to be less effective (Parsons etal., 2001a). The process of freshwater 
bathing relies upon freshwater killing the amoebae and promoting their removal 
from the gills of AGD-affected fish. It has been reported that different water sources 
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have different treatment efficacies and these appear to correlate with water hardness 
or total ionic concentration (Clark, 2002). Of all chemicals screened as alternative 
treatments for AGD, only a small handful have achieve similar results seen with 
freshwater, including chlormaine-T (Harris et al., 2004), hydrogen peroxide (Powell 
and Clark, 2003), levamisole (Findlay et al., 2000) and bithionol (Powell et al., 
2003; Florent et al., 2007b; 2007a). 
The ability to study amoeba in isolation is useful in evaluating and identifying 
parameters affecting amoeba in vivo. Studies have been undertaken in vitro to 
determine the capacity of freshwater to inactive species of amoeba under different 
conditions (Howard and Carson, 1995; Powell and Clark, 2003). The aim of this 
study was to determine the effect of bithionol and bithionol sulphoxide on the 
survival of isolated gill amoebae in vitro. We hypothesised that both bithionol and 
bithionol sulphoxide would decrease the survival of isolated gill amoeba when 
compared to seawater. 
2.3 	Materials and Methods 
2.3.1 Amoeba isolation by adherence 
The isolation of Neoparamoeba spp. for toxicity assays followed the method 
develop by Morrison et al. (2004). Briefly, donor Atlantic salmon (AS) were 
obtained from an experimental AGD infection tank post-mortem (School of 
Aquaculture, University of Tasmania). All Atlantic salmon used displayed gross 
signs of AGD (raised white mucoid patches on the gills). Gill baskets were excised 
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from the AS, centrifuged at 400 g for 2 min in distilled water and rinsed with clean 
seawater three times, dislodging amoeba from the gills. The amoebae in seawater 
were allowed to adhere to Petri dishes for approximately 2 h at 18°C. Following, 
plates were washed with seawater and approximately 20 mL of seawater was added. 
The amoebae were allowed to adhere to Petri dishes overnight at 18°C. The 
adherent cells were removed by the addition of 1 mL Hanks balanced salt solution 
with trypsin and ethylenediaminetetraacetic acid (EDTA) (Appendix 1), washed, 
centrifuged at 400 g for 5 min and concentrated. An aliquot of amoeba isolate was 
stained with 0.5% trypan-blue-seawater mix at a dilution of 1:1 and live amoeba 
(those not taking up the stain) counts were determined using a haemocytometer 
(Neubauer, BS 748). Three replicate counts were made with 18 large squares 
counted per replicate. 
2.3.2 In vitro toxicity assay 
The in vitro toxicity assays used a modified version of the assay developed by 
Powell etal. (2003). The in vitro toxicity assay involved the use of previously 
isolated live amoeba which were adhered to flat bottom, 96 well plates and then 
exposed to different treatments. The amoeba solution was prepared by either 
concentrating or diluting to create approximately 10 000 cells in 150 p.1, per well 
and allowed to adhere for 1.5 h at 18°C. 
Eight treatments were examined and assays ran for a period of 72 h. The number 
of live amoeba was determined at 0, 24, 48 and 72 h of exposure using the trypan-
blue exclusion assay (described above). Times were chosen based on previous 
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literature (Powell etal., 2003). All 96 wells were used allowing each treatment 
three replicates per day and each experiment was repeated eight times to give n 
equal to 24 per treatment. Survival of amoeba were calculated as a percentage of 
seawater control (conducted at the same time) to ensure consistency among 
treatments. For consistency with literature, the effective concentration (EC) at each 
time point was calculated. At each time point, concentration was plotted against 
percent survival for all, axes were logged (base 10 log) and a regression line was 
fitted. From this regression line, the time for 50% of the population to reach 
morbidity (EC50) was determined for all treatments (Sprague, 1969). 
2.3.3 Treatments 
All test solutions were aerated to 100% air saturation and brought to 18°C before 
commencement of each experiment. Amoebae were exposed to either bithionol 
(Experiment 1) or bithionol sulphoxide (Experiment 2) (Sigma-Aldrich, Sydney, 
Australia) at 0, 0.1, 0.5 1, 5, or 10 mg L -1 . Concentrations were chosen to include 
and expand upon previous literature (Powell et al., 2003). Bithionol and bithionol 
sulphoxide treatments were prepared making a stock solution using a mortar and 
pestle in order to create a suspension as they are both insoluble in water and then 
diluting to make the necessary concentrations. There were several controls 
examined including seawater (35%o, negative control), freshwater (de-chlorinated 
municipal source, positive control) and alumina at 10 mg L 1 (Sigma-Aldrich, 
particulate control). 
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2.3.4 Statistical Analyses 
Statistical analysis was conducted using SPSS for Windows ® (version 15.0). A 
one-way analysis of variance (ANOVA) was used to determine differences between 
assays. If no significant differences were found, assays were pooled and a two-way 
ANOVA was used to analyse means with time and treatment as factors. The 
interaction between time and treatment was examined first; if p>  0.05, there was an 
interaction and the factors of time and treatment were combined and a Tukey's 
post-hoc test conducted on the combined variable-to identify where the differences 
occurred. Homogeneity was determined using a residual plot and Levene's test; 
where the data were not normally distributed or variance homogeneous, a square 
root transformation was used. A result was considered significant if p < 0.05 and 
results are presented as mean ± standard error of the mean (SEM). Survival of 
amoeba was calculated as a percentage of seawater control (conducted at the same 
time) to ensure consistency among treatments using the following equation. 
number of amoeba in treated group 
% of seawater control = [ 	 lx 100 
number of amoeba in seawater control group 
2.4 	Results 
Survival in seawater controls was equal to or better than initial concentrations 
observed at time 0 and are given as 100% survival. Amoebae survived when 
exposed to 10 mg L-1 alumina for the 72 h duration and were determined to be not 
significantly different from the seawater controls for both Experiment 1 and 2 
(F31,736= 413.356, p <0.001, Fig 2.4-1, F31,736 = 280.358, p <0.001, Fig 2.4-2, 
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respectively). Amoebae numbers declined rapidly when exposed to freshwater with 
a 94% relative reduction from the seawater control seen within the first 24 h in 
Experiment 1 and no viable amoebae were observed at any time points after time 0 
(Fig 2.4-1). A similar result was seen in Experiment 2 with a 96% relative reduction 
in freshwater amoeba numbers from 0 to 24 h when compared to the seawater 
control (Fig 2.4-2). For both Experiment 1 and 2 EC50 values were calculated at 
each time point (Table 2.4-1). 
Table 2.4-1. The effective concentration (mg L -1 ) needed to cause 50% mortality 
(EC50) in Neoparamoeba spp. when exposed to bithionol (BT) or bithionol 
sulphoxide (BTS) for 0, 24, 48 or 72 h. 
Oh 	24h 	48h 	72h 
BT 	n/a 	 7 mg L-1 	0.65 mg L -1 	0.32 mg L -1 
BTS 	n/a 	 n/a 	 0.35 mg L -1 	0.11 mg L 1 
Note: Not applicable (n/a) indicates that 50% mortality had not occurred at the 
time point. 
In Experiment 1 bithionol was effective at reducing amoebae numbers 
significantly at all concentrations and time points (F31,736=  413.356, p <0.001, Fig 
2.4-1). When amoebae were treated with 10 mg L -1 of bithionol, there was a 53% 
relative reduction from 0 to 24 h when compared to seawater and by the 
culmination of the assay there was a final reduction of amoeba similar to that seen 
with freshwater. For bithionol at 5 mg I: 1 a 95% relative reduction from seawater in 
amoeba numbers was observed which is similar to freshwater and bithionol at 10 
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and 1 mg L-1 following a 72 h treatment (Fig 2.4-1). There was a continuing 
decrease in amoeba numbers as time progressed across all bithionol treatments. At 
the culmination of the assay, the greatest reduction in amoeba numbers from 
seawater of 100,95 and 92% was seen in the 10,5 and 1 mg L -1 treatments, 
respectively. Both the 0.5 and 0.1 mg L -1 significantly reduced amoeba number 
compared to the seawater control; however the relative percent reduction at 72 h 
was 87 and 82%, respectively, which was significantly higher than the other 
bithionol treatments (F3 1 ,736— 413.356, p < 0.001, Fig 2.4-1). 
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Fig 2.4-1. Effect of time and treatment on mean (± SEM) number of viable 
isolated amoeba (as a percentage of the seawater control) when exposed to either 
-1 freshwater (■), 10 mg L alumina (EZZ:1), seawater ( 
 
), or bithionol at 0.1, 
 
 
0.5, 1, 5 and 10 mg Li (1 	1,1 	I, 
    
I 	I , and Rum respectively) (n = 24). 
Seawater controls remained at 10 000 cells well' and are presented as 100% 
survival. Common letter across both time and treatment indicates no significant 
different using a Tukey's test (p > 0.05). 
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Bithionol sulphoxide examined in Experiment 2 reduced amoebae numbers 
significantly when compared to the seawater control at all concentrations and time 
points (F31,736 = 280.358, p < 0.001, Fig 2.4-2). When treated with 10 mg U l there 
was a 57% relative reduction compared to seawater in amoeba from 0 to 24 h and 
by the culmination of the assay this relative reduction of amoebae was 99% when 
compared to seawater, which was similar to that seen with freshwater. For the 
5 mg U i treatment there was a 96% relative reduction in amoeba compared with 
seawater, which is similar to freshwater and bithionol at 10 and 1 mg U l following 
a 72 h treatment (Fig 2.4-2). Similar to bithionol, there was a continuing decrease in 
amoeba numbers as time progressed across bithionol sulphoxide treatments with the 
exception of the 0.5 and 0.1 mg 1_, -1 treatments. At the culmination of the assay, the 
greatest reduction in amoeba when compared to the seawater control of 99, 96 and 
91% was seen in the 10, 5 and 1 mg U l treatments, respectively. Both the 0.5 and 
0.1 mg U l significantly reduced amoeba numbers compared to the control. 
However, the relative percent reduction at 72 h was 59 and 60%, respectively, 
which was significantly higher than the other bithionol treatments (F31,736 = 
280.358, p < 0.001, Fig 2.4-2). Both the 0.5 and 0.1 mg U l treatments appeared to 
plateau out after 48 h with no further decrease observed after 72 h. 
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Tune (h) 
Fig 2.4-2. Effect of time and treatment on mean (± SEM) number of viable 
isolated amoeba (as a percentage of the seawater control) when exposed to either 
freshwater (■), 10 mg L-1 alumina (EZZ:1), seawater (ordw), or bithionol 
sulphoxide at 0.1, 0.5, 1, 5 and 10 mg L 1 (1 	I, I 	I 	I 	I and 
respectively) (n = 24). Seawater controls remained at 10 000 cells well -1 and are 
presented as 100% survival. Common letter across both time and treatment 
indicates no significant different using a Tukey's test (p > 0.05). 
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2.5 	Discussion 
Across all in vitro toxicity assays seawater controls were equal to or better than 
• 
initial controls indicating that conditions were appropriate to observe growth. 
Present investigations identified that bithionol and bithionol sulphoxide used in 
vitro were successful at reducing amoeba numbers relative to seawater controls. 
When examining the alumina (particulate control) amoeba numbers did not differ 
from the seawater controls, indicating that the particulate matter in the treatment did 
not adversely affect amoebae survival over a 72 h period which is consistent with 
other studies (Powell etal., 2003). The lowest dose able to kill a significant number 
of amoeba (>50%) was 0.1 mg L' 	1 mg 1_," for bithionol and bithionol 
sulphoxide, respectively. 
In Experiment 1 and 2 when comparing freshwater to the seawater controls a 94 
and 96% relative reduction were observed, respectively. The amoeba numbers 
declined rapidly in freshwater which is similar to other studies (Howard and 
Carson, 1993; Powell and Clark, 2003) indicating that freshwater was the most 
effective fast acting treatment. However, following the 72 hr toxicity assay 
bithionol successfully reduced amoebae numbers to similar levels as freshwater at 
concentrations of 5 and 10 mg Li . A similar result was seen with bithionol 
sulphoxide at 1, 5 and 10 mg L -1 , where amoebae numbers were reduced to a 
similar level as that seen with freshwater. Bithionol when used at 0.1, 0.5 or 
1 mg 1_, -1 was successful in reducing amoebae numbers albeit not as effective as 
freshwater or higher bithionol concentrations. Bithionol sulphoxide at the lower 
concentrations of 0.1 and 0.5 mg 1_, -1 were the least effective reducing amoebae 
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numbers by 50%. However, even reducing the amoebae numbers by half would 
theoretically half the number of baths. When examining the cost of bithionol and 
bithionol sulphoxide the price difference is considerable with bithionol eight times 
more expensive than bithionol sulphoxide. Thus bithionol sulphoxide if as effective 
as bithionol is a significantly cheaper alternative. 
To date, the only commercially viable and effective treatment for AGD is 
freshwater bathing. Several compounds have been screened for in vitro toxicity 
including various antimicrobials, antiparasiti .c, disinfectants and detergents with 
varying success. Of all chemicals screened only a small handful have achieved 
similar results seen with freshwater, including chlormaine-T (Harris et al., 2004), 
hydrogen peroxide (Powell and Clark, 2003), levamisole (Findlay etal., 2000) and 
bithionol (Powell etal., 2003; Florent et al., 2007b; 2007a). However, for some of 
these treatments they were most effective.when added to a freshwater bath, hence 
still maintaining reliance upon freshwater bathing to treat AGD. 
Studies examining the chemical control and treatment of Neoparamoeba spp. 
(Powell etal., 2003), Hexamita salmonis (Tojo and Santamarina, 1998a), 
Gyrodactylus spp. (Tojo and Santamarina, 1998c), Ichthyobodo necator (Tojo etal., 
1994a; Tojo and Santamarina, 1998b), Microcotyle sebastis (Kim and Choi, 1998), 
Pseudodactylogyrus spp. (Buchmann et al., 1992) and Trichodina jadranica 
(Madsen etal., 2000) have all examined bithionol and in some cases bithionol 
sulphoxide in vitro and in vivo as bath and oral treatments. When examining the 
literature, studies show that bithionol exhibited mixed results of toxicity; however, 
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it was reported to be effective in vitro and in vivo as both bath and oral treatments, 
successfully reducing the parasite load. However, with the scale and intensity of 
salmonid farming occurring in Australia, a bithionol bath treatment would be 
impractical, as it is insoluble and would require a large amount of the compound to 
treat the bath water, thus making it labour and cost intensive. On the other hand, 
with the determination of toxicity to the target animal and its efficacy .with respect 
to AGD it would be possible to incorporate bithionol in-feed and assess as a 
treatment for the control of AGD in Atlantic salmon. Furthermore, with the 
increasing need for the use of chemotherapeutants in aquaculture, it is very 
important to minimise the accumulation of chemicals in food for human 
consumption and the effect on the environment. Producing an in-feed treatment 
would assist in alleviating the release of large amounts of the compound into the 
surrounding water (Findlay et al., 2000). 
Bithionol and bithionol sulphoxide have been used as a successful treatment for 
numerous human disease including paragonimiasis (oriental lung fluke) and 
fascioliasis (liver fluke) (Yang and Lin, 1967; Bacq et al., 1991). However, 
bithionol sulphoxide was found to have stronger anthelminthic activity than 
bithionol when examined in rats (Meshi et al., 1970). Interestingly in this study, 
bithionol and bithionol sulphoxide exhibited similar reductions at high 
concentrations; however, at concentrations 0.5 mg L -1 or lower bithionol sulphoxide 
was not as effective as bithionol. Bithionol and bithionol sulphoxide have also been 
examined as possible treatments for natural rumen fluke infection in cattle and 
tapeworm infections in cats, dogs, sheep and chickens (Enzie and Colglazier, 1960; 
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Prasittirat etal., 1997). Neoparamoeba spp. were susceptible to both bithionol and 
bithionol sulphoxide with median effective concentration (ECH) at 48 h of 0.35 and 
0.65 mg L -1 respectively and 0.11 and 0.32 mg L -1 at 72 h. The cladoceran, Daphnia 
magna, and the rotifer, Brachionus calyciflorus, were both found to be susceptible 
to bithionol with 48 h and 24 h EC50 values of 0.063 and 0.3 mg L -1 respectively 
(Yoshimura and Endoh, 2005). Bithionol was identified as toxic to medaka, Oryzias 
latipes, with a 96 h median lethal concentration (LC50) of 0.24 mg L -1 , toxicity will 
be analysed further in Chapter 3 with the indication that medaka's LC50 is well 
within the therapeutic range in salmonids. In order for bithionol or bithionol 
sulphoxide to be administered as a treatment it would need to be licensed. Bithionol 
is used as an ingredient in deodorants, shampoos and surgical soaps, however has 
been banned from these products by the U.S. Food and Drug Administration (FDA) 
for safety reasons (Anonymous, 2002). However, it has been used as a parasiticide 
for cattle, chicken and sheep (Enzie and Colglazier, 1960; Mourot etal., 1987). 
Bithionol is currently an investigatory drug for the Centre for Disease Control in 
America for therapeutic use in treating human paragonimiasis and fascioliasis 
(Anonymous, 2008). It is not currently licensed in Australia for use in animals or 
humans and in order to obtain a license a lot more research into the 
pharmacokinetics, tissue and blood residues and human impacts is required. 
The screening of compounds in vitro for toxicity toward Neoparamoeba spp. 
enables the identification without considerable input of possible AGD treatment 
candidates. Stage I of drug screening, the development of single- and multi-day in 
vitro toxicity assays, has allowed for the bulk testing of numerous disinfectants, 
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'antibiotics and antiprotozoal drugs. To date, few candidate drugs have moved to 
Stage II of testing, whereby salmon are offered drug-coated feed and subsequently 
experimentally challenged with Neoparamoeba spp. to determine fish toxicity and 
efficacy for preventing clinical signs of AGD. Even fewer have moved to Stage III 
testing involving field trials. This three-tiered approach has allowed for a strategic 
system for screening and identifying candidate drugs from a large pharmacopeia 
whilst maintaining effective resource management. 
Bithionol has been identified as successful in stage I and II of the three-tiered 
approach mentioned above. However, it would be advantageous to examine the in 
vitro effects of bithionol and bithionol sulphoxide on Neoparamoeba spp. in more 
detail especially looking at shorter times and higher concentrations. In order to 
continue through to stage III involving field testing it would be advantageous to 
examine the pharmacology and residue levels of bithionol and its metabolites. 
Previous studies show that bithionol may work more effectively when high 
infections pressure is observed such as that in a laboratory trial as opposed to a low 
infection pressure seen typically in a farm situation (Chapter 5). Thus examining the 
efficacy of both bithionol and bithionol sulphoxide at lower infections pressure 
would be beneficial and aid in collating data to apply for an experimental license. 
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3 Evaluation of bithionol as a bath treatment for amoebic gill 
disease caused by Neoparamoeba spp. 
Renee L. Florent, Joy A. Becker, Mark D. Powell. 
3.1 	Abstract 
This study examined the toxicity of bithionol to Atlantic salmon, Salmo salar, and 
rainbow trout, Oncorhynchus mykiss, in fresh and seawater and the efficacy of 
bithionol as a 1 h seawater bath treatment for amoebic gill disease (AGD). To 
examine toxicity, fish were bathed for 1, 3 and 6 h in bithionol, an anti-protozoal at 
0, 1, 5, 10, 25 and 35 mg U 1 with toxicity determined by time to morbidity. 
Efficacy was examined by bathing AGD-affected Atlantic salmon and rainbow 
trout for 1 h at bithionol concentrations of 1 to 25 mg U 1 . Efficacy was determined 
by examining gill amoeba counts and identifying percent lesioned gill filaments at 1 
and 24 h after bath exposure to bithionol. For both species, bithionol was 
determined to be toxic at 25 and 35 mg L exhibiting median lethal times (LT50) 
ranging from 21 to 84 min. Morbidity occurred in the 5 and 10 mg U 1 treatments. 
However, due to the sampling regime there were not enough fish available to 
calculate LT50. Only bithionol at 1 mg L was considered non-toxic with no signs 
of morbidity. Bithionol appeared to be more toxic in seawater than freshwater and 
had no acute effects on gill Na +/K+ ATPase and succinic dehydrogenase (SDH), or 
plasma osmolality and chloride concentration. Bithionol at 1 mg U 1 reduced 
percent lesioned gill filaments in Atlantic salmon and rainbow trout by 33 and 27% 
respectively, compared to the seawater control. Similarly, numbers of amoeba were 
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reduced by 33 and 43% for Atlantic salmon and rainbow trout respectively, when 
compared to the seawater control. Furthermore, bithionol reduced percent lesioned 
gill filaments as much as did the current industry standard of freshwater. This study 
demon§trated that a 1 h seawater bath containing 1 mg 1_, -1 bithionol could be an 
improvement to the current method of treatment for AGD-affected Atlantic salmon 
. and rainbow trout. 
3.2 	Introduction 
Aquaculture involves intensive animal husbandry, maintaining large numbers of 
animals in a relatively limited space; these large numbers and limited space have 
lead to an increased risk of disease outbreaks (Stoffregen etal., 1996). Parasites are 
provided with optimal conditions, as culture conditions contribute to rising water 
temperature and poor water quality, thus leading to significant fish loss (Schmahl et 
al., 1989). Hence, the ongoing need for control of such diseases is paramount. 
Recent investigations have focused on antiprotozoals to keep farmed fish such as 
rainbow trout and Atlantic salmon disease free (Santamarina etal., 1991). 
Successful elimination of endoparasites, such as nematodes and cestodes, has been 
achieved using oral administration of drugs including levamisole and praziquantel, 
whereas bath administration is generally used in treating ectoparasites, such as a 
formalin bath to treat trichodinads and monogeneans (Noga, 2000). 
Significantly problematic to Australian salmon aquaculture, amoebic gill disease 
is caused by the protozoan parasite Neoparamoeba spp. (Munday etal., 2001). 
Neoparamoeba spp. is a free-living marine amphizoic amoeba that attaches itself to 
- 46 - 
Chapter Three 	 Bithionol bath toxicity and efficacy 
the gills particularly the secondary lamellae (Adams and Nowak, 2003). It is 
characterised macroscopically by the presence of raised, white mucoid patches with 
histological presentation of single or multi-focal epithelial hyperplasia leading to 
lamellar fusion (Parsons etal., 2001a; Adams etal., 2004). Freshwater bathing of 
affected fish is the current commercial management strategy for AGD; it lowers 
gross gill lesions, mortalities and is environmentally friendly (Munday and Zilberg, 
2003); however, it is labour and cost intensive as well as stressful to the fish 
(Parsons etal., 2001a; Munday and Zilberg, 2003). Attempts to identify potential 
chemotherapeutic agents have been limited due to either target fish toxicity or the 
cost of treatment (Alexander, 1991; Howard and Carson, 1994). Toxicity of several 
compounds to Neoparamoeba spp. has been examined in vitro including levamisole 
(Howard and Carson, 1995), chlorine dioxide, chloramine-T, hydrogen peroxide 
(Powell etal., 2003; Powell and Clark, 2003), amprolium, albendazole, toltrazuril, 
and bithionol (Powell et al., 2003). Howard and Carson (1994) reported that 
levamisole at concentrations? 10 ppm in vitro were lethal to N. pemaquidensis and 
chloramine-T concentration of 25 and 50 ppm effectively reduced amoeba numbers 
to deionised water equivalents after 2 h (Powell and Clark, 2003). Powell et al. 
(2003) found amprolium at 1 mg 1_, -1 and bithionol at 1 and 10 mg L i to be 
amoebicidal in vitro. From these studies, it was stated that chloramine-T and 
bithionol showed promise and would be suitable AGD treatments for in vivo 
examination (Powell and Clark, 2003). 
Bithionol has been examined in vitro and in vivo as a bath treatment for other 
salmonid parasites, such as Gyrodactylus sp. and Ichthyobodo necator. Santamarina 
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et al. (1991) observed limited toxicity and complete in vitro efficacy against 
Gyrodactylus sp. in rainbow trout at 12.5 mg L-1 , with a minimum 20 mg L -1 
reported as efficacious in vivo. Tojo etal. (1994b) stated that bithionol was 
efficacious in vivo against I. necator in rainbow trout at 25 mg L -1 for a 3 h bath on 
two consecutive days, higher concentrations exhibited some mortality. Finally, 
Madsen etal. (2000) determined that bithionol at 0.1 mg L -1 was an effective 
treatment against trichodiniasis in European eels, Anguilla anguilla, but found 
bithionol to have a relatively narrow therapeutic index. 
This study aimed to determine the efficacy of bithionol as a bath treatment for 
AGD. The first objective was to evaluate the toxicity of bithionol administered via a 
bath treatment to Atlantic salmon and rainbow trout held in either fresh or seawater 
using concentrations between 1 and 35 mg L -1 . The second objective was to 
evaluate the efficacy of bithionol at 1 to 25 mg L -1 as a bath treatment for AGD-
affected Atlantic salmon and rainbow trout. 
, 3.3 	Materials and Methods 
3.3.1 Toxicity Study 
3.3.1.1 Fish Husbandry 
Juvenile diploid mixed sex rainbow trout (RBT), with a mass of 74.5 ± 1.0 g and a 
fork length of 18.5 ± 0.1 cm (N=234) were obtained from Sevrup Fisheries 
(Tasmania, AuStralia). Atlantic salmon (AS) diploid mixed sex spring smolts, with 
a mass of 74.1 ± 0.9 g and a fork length of 18.8 ± 0.1 cm (N = 234) were obtained 
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from SALTAS salmon hatchery (Tasmania, Australia). Both groups of fish were 
maintained at the University of Tasmania Aquaculture Centre for a minimum of 
three weeks prior to experimental use. Fish were housed in two 3000 L Rathburn 
tanks with recirculated water and individual biofilter systems. Half of each species 
were housed in freshwater (de-chlorinated municipal source, 15.5 ± 1.0°C) and the 
other half of each species were maintained in seawater (35%o, 1 p.m filtered, 15.5 ± 
1.0°C). The tanks received constant aeration and oxygen levels were monitored 
daily using a Handy Gamma Oxy Guard (Birkerod, Denmark). Fish were fed twice 
daily to satiation and feed was withheld one day prior to bath administration. 
Immediately prior to bath treatment, nine fish were sampled as pre-experimental 
controls (see below). 
3.3.1.2 Bath Administration 
Bithionol concentrations of 0, 1, 5, 10, 25, and 35 mg L -I were examined for 
Atlantic salmon and rainbow trout toxicity using a maximum 6 h bath duration. 
Toxicity was examined in both freshwater (fw) (municipal source, 15.5°C, pH 7) 
and seawater (sw) (35%0, 15.5°C, pH 8.2). Baths were conducted in triplicate with 
six fish in 20 L plastic tubs at stocking densities ranging between 19.8 and 
24.4 g 	Tubs received constant aeration, with oxygen levels monitored every 15 
min and maintained at 95% saturation using oxygen, if required. Temperature, 
- salinity, pH, ammonia, nitrate and nitrite were measured hourly throughout bath 
duration. Bithionol (Sigma-Aldrich Pty. Ltd, Castle Hill, Australia) is insoluble in 
water, so it was administered as a suspension prepared using 1 mL of bath water 
and a mortar and pestle (Tojo et al., 1994b), with some precipitation occurring at 
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concentrations > 10 mg 	In all cases, fish were euthanized using clove oil at a 
concentration of 0.02% w/v. All procedures were conducted in accordance with the 
Australian code of practices for the care and use of animals for scientific papers (7 th 
edition) under administration of the University of Tasmania Animal Ethics 
Committee. 
3.3.1.3 Data Collection 
Fish were sampled (two fish per tub) at 1, 3 and 6 h, unless fish were identified as 
moribund. Morbidity was determined as fish that were swimming slowly, close to 
the water surface or exhibiting loss of equilibrium. For each fish, mass, fork length 
and if appropriate time to morbidity were recorded and blood was sampled for 
plasma analysis. Gill tissue was processed for histology and biochemical analysis 
(see below) and liver tissue was processed for histology. Immediately following 
collection, blood was centrifuged for 2 min at 8 000 x g using a Spinwin MC-01 
(Tarsons Products Pty. Ltd. Minto, Australia), the serum was decanted and frozen. 
Gill tissue was snap frozen in liquid nitrogen for biochemical analysis and stored at 
-80°C until analysis could be performed. Plasma samples were thawed and 
osmolality determined using a Wescor Vapro 5520 vapour pressure osmometer 
(Helena Laboratories Pty. Ltd., Mount Waverly, Australia). Chloride levels were 
determined using plasma diluted 1000 X with deionised water following the 
spectrophotometric method of Zall et al. (1956). 
Thawed tissue samples for the 0, 10 and 35 mg L-I were examined for Na ±/K+ 
ATPase and succinic dehydrogenase (SDH) activity. If differences were found 
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between the above treatments then other concentrations were examined. Na ÷/K+ 
ATPase activity was determined according to a method modified from McCormick 
(1993). Briefly, tissue was homogenized using an Eppendorf micro pestle 
homogeniser in ice-cold SEID (3X concentrate) (250 mM sucrose, 10 mM sodium 
ethylene-diaminetetraacetic acid (EDTA), 50 mM imidazole, 0.1 g sodium 
deoxycholic acid) and centrifuged at 5 000 x g for 30 seconds. ATPase activity was 
determined in the presence or absence of 0.5 mM ouabain (Sigma-Aldrich Pty. Ltd, 
Castle Hill, Australia) at 25°C and absorbance was measured at a wavelength of 340 
nm for ten minutes at ten second intervals. Succinic dehydrogenase was determined 
using the spectrophotometric method as used by Powell et al. (2001). 
For consistency with literature, the time for individuals to reach morbidity was 
determined lethal time (L-T) assuming there was no recovery from morbidity. Time 
to morbidity was plotted against percent cumulative morbidity for all groups at 25 
and 35 mg L' i , axes were logged (base 10 log) and a regression line was fitted. 
From this regression line, the time for 50% of the population to reach morbidity 
(LT50) was determined for all groups (Sprague, 1969). Median lethal times were 
obtained for bithionol concentrations 25 and 35 mg L' I for fresh and seawater 
Atlantic salmon and rainbow trout as morbidity occurred prior to first sampling 
period. 
3.3.1.4 Histology 
The left gill basket was excised, rinsed gently in 0.211M filtered seawater and 
fixed in seawater Davidson's fixative and the liver was fixed in 10% neutrally 
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buffered formalin for 24 h and then transferred to 70% ethanol. The second left 
anterior hemibranch was removed, along with a small section of liver, dehydrated, 
embedded in paraffin wax, sectioned at 5 um, and stained with haematoxylin and 
eosin (H & E). The sections were viewed under a light microscope (Olympus, 
Hamburg, Germany) at X100 to X400 magnifications. Sections were examined for 
pathological changes including epithelial separation, aneurisms, change in 
pavement cells, chloride cells, hyperplasia, and inflammation (MaHatt, 1985; 
Takashima and Hibiya, 1994). 
3.3.2 Efficacy Study 
3.3.2.1 Fish Husbandry 
Juvenile diploid mixed sex RBT, with a mass of 133.9 ± 6.0 g and a fork length of 
24.0 ± 0.3 cm (N = 42) were obtained from Sevrup Fisheries. Atlantic salmon 
diploid mixed sex spring smolts, with a mass of 92.0 ± 2.4 g and a fork length of 
20.3 ± 0.2 cm (N = 108) were obtained from SALTAS salmon hatchery. Following 
laboratory exposure to Neoparamoeba spp., (see below) all fish exhibited gross 
signs of AGD according to Munday et al. (2001). Atlantic salmon and RBT were 
housed separately in two seawater (35%o, 1 um filtered, 17.0 ± 0.8°C) re-circulation 
systems, consisting of three 590 L tanks, a 500 L header and a 500 L sump 
providing a total system volume of 2770 L. The tanks received constant aeration 
and oxygen levels were monitored daily. Fish were fed twice daily to satiation and 
feed was withheld one day prior to bath administration. Immediately prior to bath 
treatment six fish were sampled as pre-experimental controls (see below). 
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3.3.2.2 Amoeba isolation and exposure 
Naïve experimental AS and RBT were exposed to Neoparamoeba spp. according 
to Morrison et al. (2004). Briefly, eight donor Atlantic salmon were obtained from 
an experimental AGD infection tank post-mortem (School of Aquaculture, 
University of Tasmania, Launceston, Tasmania, Australia). Gill baskets were 
excised from the AS, centrifuged in distilled water, and rinsed with seawater three 
times, dislodging amoeba from the gills. The amoebae in seawater were allowed to 
adhere to Petri dishes for approximately 2 h at 18°C. Plates were then washed with 
seawater and approximately 20 mL of seawater was added. The amoebae were 
allowed to adhere to Petri dishes overnight at 18°C. The adherent cells were 
removed by the addition of 1000 uL Hanks balanced salt solution with trypsin and 
EDTA (Appendix 1), washed, centrifuged and concentrated. Live amoeba counts 
were determined using a haemocytometer (Neubauer, BS 748). Three replicate 
counts were made with 18 large squares counted per replicate. The isolation 
obtained 2 500 000 amoebae delivering a final concentration of approximately 300 
cells U' persystem. 
Following bath treatments, Neoparamoeba'spp. were re-isolated from the gills 
using a technique modified from Howard and Carson (1995) and Powell and Clark 
(2003). Briefly, the right gill basket was excised and rinsed gently in 0.2 gm 
filtered seawater and individual arches were scraped with a bacterial spreader to 
remove mucus. Mucus was collected in individual 50 mL centrifuge tubes and re-
suspended in sterile seawater up to 10 mL. A 100 1.11_, aliquot of mucus-amoeba 
suspension was sampled and stained with 0.05% trypan blue viability stain at a 
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dilution of 1:1. Live amoeba counts were determined using a haemocytometer. 
Three replicate counts were made with 18 large squares counted per replicate. The 
total number of live amoebae per fish was then calculated and divided by the natural 
log of the fish mass to account for scaling differences in gill surface area with fish 
of different mass (Palzenberger and Pohla, 1992). 
3.3.2.3 Bath administration 
To determine bath efficacy, AGD-affected Atlantic salmon and rainbow trout 
were exposed to either a 1 h seawater bath containing bithionol concentrations of 1, 
5, 10, or 25 mg Li , a 3 h freshwater bath or a 1 h seawater bath containing alumina 
(25 mg L -1 , a particulate control). The alumina was prepared using the bithionol 
procedure described above. Baths were conducted in triplicate with six fish in 20 L 
plastic tubs at stocking densities ranging from 11.7 to 29.9 g Li . Following the 
bath, fish were returned to the 2770 L recirculation system (as described above) and 
monitored for morbidity until sampling occurred 24 h later. The baths were 
conducted using the procedure mentioned previously for toxicity trial. 
3.3.2.4 Data Collection 
Fish were sampled (two fish per tub) immediately following the bath and after 
24 h, unless fish were identified as moribund. As in the previous study, for each 
fish mass, fork length and if appropriate time to morbidity were recorded and blood 
was sampled for plasma analysis. Gill tissue was processed for histology and 
amoeba counts. Immediately following collection, blood was centrifuged for 2 min 
at 8 000 x g using a Spinwin MC-01, the serum was decanted and frozen. Plasma 
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samples were thawed and osmolality determined using a Wescor Vapro 5520 
vapour pressure osmometer. 
3.3.2.5 Histology 
The left gill basket was excised and processed for histology as described in 
section 3.3.1.4. The sections were viewed under a light microscope at X100 to 
X400 magnifications. The number of filaments exhibiting AGD lesions (Kent et al., 
1988) were counted and expressed as proportions of the total number of filaments in 
each section (Parsons et al., 2001a) and presented as percent lesioned gill filaments. 
A filament was counted only when the central venous sinus was visible in at least 
two-thirds of the filament and lamellae were of equal length bilaterally present to 
'near the tip of the filament (Speare et al., 1997). 
3.3.3 Statistical Analysis 
All values are expressed as mean ± standard error of the mean (SEM). Statistrcal 
analysis was conducted using SPSS for Windows® (version 11.5). A two-way 
analysis of variance (ANOVA) was used to determine differences between fixed 
factors of sampling time and treatment. If p? 0.05, a two-way ANOVA was used to 
determine differences between fixed factors of day and treatment. If no significant 
differences were found, results were pooled and either a two-way ANOVA was 
used to determine differences between water and bithionol concentration or a one-
way ANOVA used to determine differences between efficacy treatments. 
Homogeneity was determined using a residual plot and Levene's test; if the data 
were not normally distributed a log base 10 transformation was used. A result was 
- 55 - 
Chapter Three 	 Bithionol bath toxicity and efficacy 
considered significant if p < 0.05. Relative percent reduction (RPR) was calculated 
for crude number of amoebae and percent lesioned gill filaments using the 
following equation. 
number of amoeba in treated group 
RPR = 1 I 	  x100 
number of amoeba in control group 
3.4 	Results 
3.4.1 Toxicity Study 
Median morbidity times were determined in all groups at bithionol concentrations 
of 25 and 35 mg L -1 (Table 3.4-1). Atlantic salmon in freshwater at 25 and 35 mg L -1 
had an LT50 of 86 and 44 min compared to seawater values of 35 and 21 min, 
respectively. 
A similar trend was seen with RBT at 25 and 35 mg L -1 in freshwater having 
median lethal times of 51 and 46 min compared to seawater RBT of 29 and 22.5 
min, respectively. For all groups, the number of moribund fish over the 6 h bath 
duration was recorded in Table 3.4-2. At concentrations of 25 and 35 mg L -1 all 
groups exhibited 100% morbidity within 3 h. One hundred percent morbidity was 
observed at 10 mg L -1 within 3 h in both fw and sw RBT, which was the same for 
sw AS but not fw AS, which had five (27%) moribund fish after 6 h. At 5 mg L -1 
there were indications that bithionol may be more toxic in seawater with 12 (66%) 
and 5 (27°/0) . RBT and AS moribund compared to freshwater with I (5%) and 0 
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RBT and AS moribund, respectively. There was no morbidity observed in the 0 and 
1 mg 1_, -1 treatments across all groups. 
Table 3.4-1. Median lethal time and inter-quartile range (IQR) for seawater (sw) 
and freshwater (fw) Atlantic salmon (AS) and rainbow trout (RBT) exposed to a 1 
hour bithionol bath at a concentration of 25 or 35 mg L i . 
Median lethal time (mm± IQR) 
Concentration (mg L -1 ) 	sw AS 	sw RBT 	fw AS 	fw RBT 
35 ± 13 	29±10 	86±47 	51 ± 15 
35 	 21 ± 12 	22.5±11 	44±10 	46±15 
Note: (n = 18) 
With increasing bithionol concentration, plasma osmolality, plasma chloride, gill 
Na+/K+ ATPase activity and gill SDH were not significantly different for both 
species within each water source (Fig 3.4-1 and Fig 3.4-2) (all p> 0.122). This was 
comparable with histological results in which no pathology was seen in any of the 
treatments (histology not shown). As expected, plasma osmolality increased from 
freshwater to seawater observed in both species ranging from 30-100 mmol kg' (p
<0.001, Fig 3.4-1 ia, iia). Similarly, differences were found between freshwater and 
seawater in both AS and RBT gill Na47K+ ATPase activity exhibiting an 
approximate 2.5 times increase across all treatments from fw to sw (p < 0.001, Fig 
3.4-2. ia, iia). 
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Table 3.4-2. The number of moribund Atlantic salmon and rainbow trout in both 
freshwater (fw) and seawater (sw) observed at varying bithionol concentrations 
over a 6 hour (h) period. 
Concentration (mg L -1 ) Number of moribund (sw, fw) 
Atlantic salmon 0-1 h 1-3 h 3-6 h 
0 0,0 0,0 0,0 
1 0,0 0,0 0, 0 
5 4,0 1,0 0,0 
10 18, 0 na, 3 na, 2 
25 18, 6 na, 12 na, na 
35 18, 18 na, na na, na 
Rainbow trout 
0 0,0 0,0 0,0 
1 0,0 0,0 0, 0 
5 2,0 6,1 4,0 
10 18,4 na, 14 na, na 
25 18,9 na, 9 na, na 
35 18, 18 na, na na, na 
Note: Not applicable (na) indicates there were no fish left at the time point (n = 
'18) 
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Fig 3.4-1. Mean (± SEM) (a) plasma osmolality and (b) plasma chloride for 
freshwater (open circle) and seawater (closed circle) (i) Atlantic salmon and (ii) 
rainbow trout when exposed to varying bithionol bath concentrations. Asterisks 
denotes a significant difference between fresh and seawater. 
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Fig 3.4-2. Mean (± SEM) (a) gill Na + / KtATPase activity and (b) gill succinic 
dehydrogenase (SDH) activity for freshwater (open circle) and seawater (closed 
circle) (i) Atlantic salmon and (ii) rainbow trout when exposed to varying 
bithionol bath concentrations. Asterisks denotes a significant difference between 
fresh and seawater. 
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3.4.2 Efficacy 
Bithionol bath toxicity and efficacy 
For both AS and RBT, the number of morbid fish over the 1 h bath duration and 
during the following 24 h was recorded in Table 3.4-3. During the 1 h bath AS and 
RBT exhibited 100% morbidity at 25 mg 	Morbidity of 44% and 16% was 
observed during the first hour for both AS and RBT at 10 mg L -1 , respectively; 
however, no morbidity was reported in fw, 0, 1 and 5 mg L treatments. Twenty 
four hours post bath, AS in the 10 mg L -I treatment exhibited 44% morbidity, with 
no morbidity observed for other salmon. Whereas RBT had morbidity across all 
bithionol treatments, with one (16%) morbid fish in both the 1 and 5 mg L -I 
treatments and four fish (66%) in 10 mg L -I . There was no morbidity observed for 
RBT or AS in the 0 mg L -I or freshwater treatments. 
Table 3.4-3. The number of moribund Atlantic salmon (AS) and rainbow trout 
(RBT) with amoebic gill disease observed between 0 and 1 hour (0-1 h) and 1 and 
24 hours (1-24 h) when exposed to either a freshwater control bath or a 1 hour bath 
at varying bithionol concentrations. 
Number of moribund 
Concentration mg L -1 
0-1 h fw 0 1 	. 5 10 25 
AS 0 0 0 0 4 9 
RBT 0 0 .0 0 1 	. 6 
1-24 h 
AS 0 0 0 0 4 na 
RBT 0 0 1 1 4 na 
Note: (AS n = 9, RBT n = 6) Not applicable (na) indicates no fish were left at time 
point. 
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There was a concentration dependant decrease in percent lesioned gill filaments in 
both Atlantic salmon and rainbow trout (Fig 3.4-3a). For AS, the lowest 
concentration of bithiohol tested (1 mg 1: 1 ) significantly reduced percent lesioned 
gill filaments to similar levels of the fw control, with all other bithionol 
concentrations having significantly reduced percent lesioned gill filaments in 
comparison to the sw control (p < 0.001, Fig 3.4-3a). A similar pattern was 
observed in RBT, with all bithionol concentrations significantly reducing percent 
lesioned gill filaments compared to the sw control, although they were not reduced 
to a similar level seen in the fw control (Fig 3.4-3a). 
Concurrently, there was a bithionol concentration dependant decrease in amoeba 
numbers on the gills of AS and RBT following the 1 h bath (p <0.001, Fig 3.4-3b). 
Atlantic salmon exposed to a 1 h bithionol bath at 1, 5, 10 or 25 mg 1_, -1 had a 
relative percent reduction in amoeba numbers when compared to the sw control of 
of 33, 46, 47 and 60 %. respectively. Rainbow trout similarly at corresponding 
concentrations exhibited relative percent reductions of amoeba numbers compared 
to sw control of 43, 49, 56 and 60%, respectively. There were no differences in 
plasma osmolality at any of the treatment concentrations for both AS and RBT (p > 
0.078, Fig 3.4-3c). 
- 62 - 
b) 	600 
500 
400 
300 
200 
100 A
m
oe
ba
  n
u
m
be
rs
  (
x
10
3)
  
Bithionol bath toxicity and efficacy Chapter Three 
 
P
er
ce
nt
  le
si
on
ed
 g
il 
fil
a
m
en
ts
  .
  
80 
70 
60 
50 
40 
   
a) 
  
 
30 
  
 
20 - A 
 
10 
  
fw 0 	1 	5 10 25 
controls 
Treatment (mg L -1 ) 
fw 0 	1 	5 10 25 
controls 
Treatment (mg L I ) 
c) 	420 
400 
cr) 
380 
360 
Z 
0 340 
6n  320 
300 
 
 
fw 0 	1 	5 10 25 
controls 
Treatment (mg/L) 
Fig 3.4-3. Mean (± SEM) (a) percent lesioned gill filaments, (b) crude amoeba 
numbers anCI (c) plasma osmolality for rainbow trout (open circle) and Atlantic 
salmon (closed circle) when administered varying bithionol bath concentrations. 
Lower and upper case letters denote significant differences within Atlantic salmon 
and rainbow trout, respectively. 
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3.5 	Discussion 
1 - Bithionol concentrations greater than 25 mg L were considered toxic with all 
fish exhibiting signs of morbidity within three hours. This was similar to results 
reported by Tojo et al. (1994b) and Santamarina et al. (1991) with significant levels 
of mortality reported in RBT at concentrations greater than 30 mg L -I ..In the 
toxicity trial, there were indications that bithionol in seawater may be more toxic 
than in freshwater, with LT 50 values for both Atlantic salmon and rainbow trout 
equal to 44 to 84 min for freshwater compared with 21 to 35 min for seawater, 
respectively. Salinity has been reported to have little influence on the tolerance of 
fish to toxicants, but fish do tolerate toxicants better in conditions similar to which 
they reside in, possibly due to lessened osmotic problems (Sprague, 1990). This 
suggests that the increased toxicity with salinity may be linked to osmotic problems. 
Plasma osmolality was higher in seawater compared to freshwater for both species 
in the toxicity trial. However, no differences were seen in plasma chloride 
-1 concentrations, which were above 160 mEq L quoted as the minimum acceptable 
level for chloride ions by Morgan and Iwama (1991), indicating the fish were not 
likely to be suffering osmotic stress. Hence, further investigation would be required 
in order to determine the mechanism for the observed difference in bithionol 
toxicity between fish held in fresh and seawater. Bithionol concentration did not 
affect plasma osmolality or plasma chloride concentration, adding to the hypothesis 
that the cause of differential toxicity between freshwater and seawater was not 
related to osmoregulation. 
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The difference between fw and sw gill Na+/K+ ATPase levels obtained in this 
study correspond to those found by Pfeiler and Kirschner (1972) who showed 
Na±/K+ ATPase levels in rainbow trout to be 12.6 ± 1.7 larnol Pi mg protein -I hi in 
freshwater and 23.6 ± 2.1 nmol Pi mg proteinh 1 in seawater. Similarly, Ventrella 
et al. (2001) reported that RBT had lower activity in fw compare to brackish water 
(22%0). The difference observed between fw and sw is attributed to the increase in 
Na+ in marine fish, which must be pumped across the gills into the environment 
(Pfeiler and Kirschner, 1972). McCormick (1993) reported Na +/K+ ATPase to be an 
ion-translocating enzyme found in high concentrations in gill chloride cells and 
believed to be the primary enzyme for excretion of excess Na+ and Ci from body 
fluids (Handeland et al., 2004). Succinic dehydrogenase, a chloride cell activity 
marker, plays an important role in mitochondria as it participates in the electron 
transport, respiratory chain and Krebs cycle (Briere et al., 2005). In both species, 
the highest concentration of bithionol did not inhibit gill Na+/K+ ATPase or gill 
SDH from the respective control group, indicating that bithionol concentration did 
not appear to impair gill ion regulatory function over the 6 h sample period. This 
was further evidenced by the absence of acute changes in plasma chloride 
concentration. No difference suggests that the two gill toxicity markers of SDH and 
Na+/K+ ATPase were not acutely affected by bithionol and the cause of toxicity was 
most likely not related to gill function. 
Both Na+/K+ ATPase and SDH were examined because bithionol is known to be a 
metabolic disruptor, uncoupling electron transport in fish ciliates including 
Tetrahymena pyriformis (Griffin, 1989) and Trichodina jadranica (Madsen et al., 
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2000). Takeuchi etal. (1984) postulated that bithionol functioned as an uncoupler 
of mitochondrial oxidative phosphorylation in the trophozoite stage of the 
Entamoeba histolytica, the main amoeba pathogenic to humans. It is suggested that 
bithionol has the ability to inhibit activity of fiimarate reductase, malie enzyme, 
phosphogluconate dehydrogenase and succinate dehydrogenase in human liver and 
lung flukes (Hamajima et al., 1979), although the inhibition of succinate 
dehydrogenase was not observed in this study. It is important to note that the assay 
used in this study examined Na ±/K+ ATPase activity, not the presence of ATP, 
therefore showing that bithionol did not inhibit Na±/K+ ATPase in the gill. There 
was no indication of the availability of ATP to drive the Na+/K+ ATPase in chloride 
cells. Longer-term exposure may affect the availability of ATP, therefore in future 
studies it would be advantageous to examine the presence of ATP in gill tissue. 
Histological sections of gill or liver tissue from all bithionol concentrations did 
not reveal any signs of alterations from the 0 mg L treatment. Chloride cells, 
mucous cells, inflammation and epithelial separation were similar across all 
concentrations; reinforcing the suggestion that bithionol did not acutely affect the 
gill. Bithionol is known to be readily eliminated by the kidneys in humans and rats, 
but accumulates in bile of mice (Barrett-Connor, 1982). Therefore future studies 
should include sampling of the anterior and posterior kidney, in addition to the liver 
and gills. 
Bithionol, at a minimum concentration of 1 mg Li , significantly reduced the 
percent lesioned gill filaments and numbers of gill amoebae in both Atlantic salmon 
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and rainbow trout compared to the seawater control fish. Moreover, the observed 
reduction in percent lesioned gill filaments in Atlantic salmon at bithionol 
-1 concentrations of 1, 5 and 10 mg L was equal to that of the current industry 
standard of a freshwater bath. Reduction in amoeba numbers after the commercial 3 
h freshwater bath when compared to a sw control have been reported to be 85-90% 
(Clark etal., 2003). A similar reduction of 90% from the sw control was seen in the 
efficacy trial with both AS and RBT freshwater baths. Atlantic salmon bathed in 
1 - bithionol at concentrations from 1 to 25 mg L exhibited a reduction in amoeba 
numbers from the sw control of 33% to 60%. Similarly, rainbow trout resulted in 
reductions of amoeba numbers from the sw control compared to 1 and 25 mg L -1 of 
43% and 60% respectively. These results indicate that a 1 h bithionol bath at 1 mg 
L-1 in sw can be as efficacious as freshwater in treating AGD, as a minimum crude 
amoeba reduction of 33% was seen compared to no treatment. 
Other treatments for AGD that have been considered in vivo include softened 
freshwater (contains fewer divalent cations, approx. 0.4 mM Ca2+), which was 
suggested to alter mucus viscosity making it more efficacious than hard freshwater 
reducing amoeba numbers and alleviating the pathological signs of amoebic gill 
disease (Roberts and Powell, 2003a). Chloramine-T, a disinfectant at 10 mg L -1 in a 
seawater bath was as effective as a freshwater bath reducing amoeba numbers by 
approximately 60%, compared to the seawater control (Harris et al., 2004). A 
similar reduction was obtained with a 1 h bithionol bath at 25 mg Li ; however, it 
was associated with high morbidity. Additionally, levamisole, the levoisomer of 
tetramisole, is a recognised antihelmintic and has been reported as effective in vitro 
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at 50 mg L -1 for Gyrodactylus spp. (Schmahl etal., 1989) and an effective 
treatment for AGD-affected Atlantic salmon at 50 mg L -1 (Munday and Zilberg, 
2003). This indicates that levamisole is almost as efficacious as freshwater for 
treating AGD, but was associated with gill damage and mortalities. In contrast, 
bithionol at 1 mg L -1 exhibited no morbidity yet was as effective as the current 
freshwater bath. 
Bithionol toxicity and efficacy is dependent upon host species and target parasite. 
A concentration of 0.1 mg L -1 was reported as a possible therapeutic for the 
protozoan parasite, Trichodina jadranica in European eels, Anguilla anguilla, due 
to its capability to effectively treat entire recirculation systems, although it exhibited 
a relatively low therapeutic index (Madsen etal., 2000). Conversely, Buchmann et . 
al. (1992) demonstrated that bithionol at 0.1 mg L -1 was not efficacious as a static 
bath against gill parasitic monogeneans, Pseudodactylogyrus sp. and concentrations 
> 1 mg L -1 were toxic, causing 100% mortality within 24 h in the European eel. 
Bithionol as a static bath has also been reported as effective in killing the ciliate 
Tetrahymena pyriformis at 60 mg Li , whilst being non-toxic to the minnow golden 
shiner, Notemigonus crysokucas (Griffin, 1989). 
For AGD-affected Atlantic salmon and rainbow trout, this study identified that a 
1 h seawater bath using a bithionol concentration of 1 mg L i exhibited no 
morbidity and reduced amoeba numbers and percent lesioned gill filaments from 
the seawater control. Nonetheless, with the scale and intensity of salmonid farming 
occurring in Tasmania, a bithionol bath treatment would be impractical as it is 
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insoluble and would require a large amount of the compound to treat the bath water. 
On the other hand, with the determination of toxicity to the target animal and its 
efficacy with respect to AGD it would be possible to incorporate bithionol in-feed 
and assess as a treatment for the control of AGD in Atlantic salmon. Furthermore, 
with the increasing need for the use of chemotherapeutants in aquaculture, it is very 
important to minimise the accumulation of chemicals in food for human 
consumption and the effect on the environment. Producing an in-feed treatment 
would assist in alleviating the release of large amounts of the compound into the 
surrounding water (Findlay et al., 2000). 
In conclusion, bithionol was toxic above 25 mg L-1 in freshwater (municipal 
source, 15.5°C, pH 7) and seawater (35%o, 15.5°C, pH 8.2) for both Atlantic salmon 
and rainbow trout. It did not appear to acutely affect the gill toxicity parameters of 
SDH, Na+/K+ ATPase activity, or the plasma osmolality, chloride and no 
pathological changes in the gill or liver tissue were found over the 6 h period. 
Bithionol was efficacious as a 1 h seawater bath for treating amoebic gill disease 
caused by Neoparamoeba spp. reducing mean percent lesioned gill filaments and 
crude amoeba numbers compared to seawater control at all concentrations 
examined. Bithionol concentrations of 1, 5 and 10 mg L produced an efficacy 
comparable to the currently used freshwater bath in Atlantic salmon. Bithionol 
warrants further investigation as a treatment for amoebic gill disease, including 
possible use as an oral medication. 
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4 Efficacy of bithionol as an oral treatment for amoebic gill 
disease in Atlantic salmon, Salmo salar 
Renee L. Florent, Joy A. Becker, Mark D. Powell. 
4.1 	Abstract 
This study examined the efficacy of bithionol as an oral treatment for Atlantic 
salmon, S. salar affected by amoebic gill disease (AGD). The current commercial 
management strategy of AGD is a costly 3 h freshwater bath. It is labour intensive 
and the number of baths needed appears to be increasing; hence there is an effort to 
identify alternative treatments. Efficacy was examined by feeding AGD-affected 
Atlantic salmon twice daily to satiation with bithionol, an antiprotozoal agent, at 25 
mg kg-1 feed. Three seawater (35%o, 17°C) re-circulation systems were used, each 
consisting of three tanks containing 32 Atlantic salmon smolts with an mean (± 
SEM) mass of 90.4 g (± 5.2). Three feeds were examined in the trial including 
bithionol, plain commercial control and oil coated commercial control. Feeding 
commenced 2 weeks prior to exposure to Neoparamoeba spp. at 300 cells L -1 and 
continued for 28 days post exposure. Efficacy was determined by examining gross 
gill score and identifying percent lesioned gill filaments twice weekly for 4 weeks 
post exposure. Bithionol, when fed as a two week prophylactic treatment at 25 mg 
-1 kg feed, delayed the onset of AGD pathology and reduced the percent lesioned gill 
filaments by 53% and halved the gill score from two to one when compared with 
both the plain and oil controls during an experimental challenge. There were no 
palatability problems observed with mean feed intake of bithionol over the trial 
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duration with fish consuming higher levels of the bithionol diet compared to both 
- the oil and plain controls. This study demonstrated that bithionol at 25 mg kg' feed, 
when fed as a two week prophylactic treatment for Neoparamoeba spp. exposure, 
delayed and reduced the intensity of AGD pathology, and warrants further 
investigation as an alternative to the current freshwater bath treatment for AGD-
affected Atlantic salmon. 
4.2 	Introduction 
Bithionol, a phenolic compound related structurally to hexachlorophene, has been 
used worldwide as a parasiticide for cattle, sheep, chickens, dogs and cats (Enzie 
and Colglazier, 1960). It is reported to have surfactant antimicrobial properties and 
thus is also effective against bacteria, moulds and yeast (Kim and Choi, 1998). It 
has been used as an alternative to praziquantel against human trematode and 
cestode infections, in particular paragonimiasis (Enzie and Colglazier, 1960; 
Takeuchi et al., 1984), and has been widely used in veterinary medicine as it is 
active against flukes and cestodes (Mourot et al., 1987). Bithionol has been found to 
stimulate lactic acid production, inhibit oxygen consumption and decrease 
glycolytic and oxidative metabolism in the human lung fluke, Paragonimus 
westermani, in vitro (Hamajima, 1973). Furthermore, it was postulated to be linked 
to a variety of processes including the inhibition of reduced nicotinamide adenine 
dinucleotide (NADH)-fumarate reductase and involved in protein phosphorylation 
(Reid etal., 2001). With regards to fish, bithionol has been shown to be effective 
against the fish ciliates Philasterides dicentrarchi in turbot, Scophthalmus maximus, 
Tetrahymena pyriformis in vitro and Trichodina jadranica in European eels, 
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Anguilla anguilla, acting upon the mitochondrial respiratory chain and uncoupling 
electron transport (Griffin, 1989; Madsen etal., 2000; Iglesias etal., 2002). 
Bithionol has been recorded as efficacious in vitro and in vivo when used as a bath 
treatment for salmonid parasites, including Gyrodactylus sp., khthyobodo necator 
(Santamarina et al., 1991; Tojo et al., 1994b) and Neoparamoeba spp. (Florent et 
al., 2007a). Furthermore, due to bithionol being insoluble in water, it was 
advantageous to use bithionol as an oral medication, providing easy administration 
and limited fish handling (Tojo and Santamarina, 1998a). Bithionol at 40 g k -g-i feed 
was offered for 10 days at 2% body weight (BW) per day to rainbow trout, 
Oncorhynchus mykiss, infected with Spironucleus salmonis, Gyrodactyhts sp. or I. 
necator and exhibited a reduction in parasitemia. Bithionol eliminated 
approximately 80% of S. salmonis from rainbow trout whilst both Gyrodactylus sp. 
and I necator infections were reduced from a high to low intensity (Tojo and 
Santamarina, 1998a; b; c). Kim and Choi (1998) reported bithionol administered in-
feed at 100-200 mg kg' BW significantly reduced the number of monogeneans 
Microcotyle sebastis on the gills of cultured rock fish, Sebastes schlegeli, with a 20 
day feeding duration being most effective. 
The protozoan parasite Neoparamoeba spp. is a free-living marine amphizoic 
amoeba and is believed to cause amoebic gill disease (AGD) (Kent etal., 1988; 
Munday etal., 1990; Adams and Nowak, 2004b). It attaches itself to the gills, 
particularly the secondary lamellae, and is characterised macroscopically by the 
presence of raised, white mucoid patches with histological presentation of single or 
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multi-focal epithelial hyperplasia leading to lamellar fusion (Adams and Nowak, 
2001). It primarily affects salmonids and is a significant problem for the Atlantic 
salmon industry in Australia (Munday et al., 2001; Nowak et al., 2002). The current 
commercial treatment for AGD is freshwater bathing of affected fish, as it lowers 
gross gill lesions, mortalities and is environmentally friendly. However, it is labour 
and cost intensive as well as requiring fish handling, hence the need for effective 
oral medications (Parsons etal., 2001a; Munday and Zilberg, 2003). 
Several compounds have been examined for efficacy against AGD, including 
levamisole (Howard and Carson, 1995), chlorine dioxide, chloramine-T, hydrogen 
peroxide (Powell et al., 2003; Powell and Clark, 2003), amprolium, albendazole, 
toltrazuril, and bithionol (Powell etal., 2003). These compounds have been 
examined either as a bath treatment or in in vitro toxicity testing in seawater, with 
levamisole reported as lethal to N pemaquidensis at concentrations? 10 ppm in 
vitro (Howard and Carson, 1994), whilst chloramine-T at a concentration of 25 and 
50 ppm reduced amoeba numbers equivalent to those seen in deionised water after 2 
h (Powell and Clark, 2003). Amprolium was found to be an amoebastat at 1 mg L -1 
and bithionol amoebicidal at 1 and 10 mg L -I in vitro (Powell and Clark, 2003). 
Compounds that have been examined as in-feed treatment for AGD include the 
mucolytic compound L-cysteine ethyl ester (LCEE), which was reported to delay 
progression of pathology associated with AGD as well as reduce percent lesioned 
gill filaments by approximately 50% relative to the control when fed at 52.7 mg kg-I 
fish d-I for two weeks (Roberts and Powell, 2005). The purpose of the present study 
was to determine if bithionol, when administered orally as a prophylactic and 
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-1 therapeutic treatment at 25 mg kg feed to Atlantic salmon, could be used as an 
effective treatment against amoebic gill disease affected Atlantic salmon. 
4.3 	Materials and Methods 
4.3.1 Fish husbandry and maintenance 
Atlantic salmon (AS) diploid mixed-sex spring smolts, with a mass of 90.4 ± 5.2 g 
and a fork length of 21.1 ± 0.3 cm (N = 288) were obtained from SALTAS salmon 
hatchery (Tasmania, Australia). Fish were maintained at the University of Tasmania • 
Aquaculture Centre for a minimum of three weeks prior to experimentation. Salmon 
were acclimated to seawater (30%0, 1 um filtered, mean ± SEM temperature of 16 ± 
0.8°C) over 14 days in one 3000 L Rathburn tank with recirculated water and an 
individual biofilter system. The tank received constant aeration and oxygen levels 
were monitored daily using a Handy Gamma Oxy Guard (Birkerod, Denmark), with 
dissolved oxygen levels of 94.0 ± 0.2% satuartion. Fish were fed a commercially 
available diet of 4 mm Atlantic Salmon Grower LE pellets (SkrettingTM, Hobart, 
Australia) twice daily to satiation throughout the seawater acclimation period. 
4.3.2 Experimental design and challenge method 
Two hundred and eighty-eight Atlantic salmon were equally and randomly 
• allocated into nine tanks at a stocking density of 6.6 ± 0.1 g Li . The tanks were in 
three separate seawater re-circulation systems, each consisting of three 590 L tanks, 
a 500 L header, and a 500 L sump providing a total volume of 2770 L. All tanks 
received constant aeration with water temperature and oxygen levels monitored 
daily. Fish were acclimated from 30 to 35 %o over seven days and allowed to 
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habituate to the systems for the following seven days, with system conditions 
maintained on a photoperiod of 12 h each of light and dark, with a water
• temperature of 16.7 + 0.3°C, pH 8.19 ± 0.01 and feeding of standard commercial 
feed prior to commencing experimental procedures. Following seven days 
conditioning, each system was randomly allocated a treatment. Treatments 
consisted of (1) commercial feed (control), (2) commercial feed coated with fish oil 
(control with oil) and (3) commercial feed coated with combination of 25 mg kg -I 
feed bithionol and fish oil. This dose was chosen based on previous work, which 
showed bithionol to be toxic when, administered as a bath treatment at 
concentrations > 10 mg L-I (Florent etal., 2007a). Fish were fed to satiation twice 
daily at 0830 h and 1630 h throughout the entire study with feed intake recorded 
daily. In order to determine tank feed intake an average pellet weight for each diet 
was obtained. Daily, the numbers of uneaten feed pellets were counted and 
multiplied by the average pellet weight, and feed intake was determined by 
subtracting the weight of uneaten feed from the feed placed into the tank. Feed 
intake was determined as a percent of the tank biomass by dividing the mean tank 
feed intake for the week by the tank biomass and multiplying by 100 to obtain the 
weekly mean feed intake as a percent of the tank weight. On Day 0 and 17, fish 
were only fed once due to weight check and sampling coinciding on these days. 
Weight checks with a minimum of ten fish per tank were conducted weekly to 
determine feed intake as percent body weight. All treatments were fed 14 days prior 
to exposure to Neoparamoeba spp. with feeding continued for a further 28 days 
after exposure. 
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Fish were experimentally exposed to Neoparamoeba spp. according to Morrison 
et al. (2004). Briefly, six donor Atlantic salmon were obtained from the University 
of Tasmania's Aquaculture Centre experimental AGD infection tank post-mortem. 
Gill baskets were excised from the salmon centrifuged in distilled water and rinsed 
with seawater three times to dislodge amoebae from the gills. Amoebae in seawater 
were allowed to adhere to Petri dishes for approximately 2 h at 18°C. Plates were 
washed with clean seawater and approximately 20 mL of seawater was added. 
Amoebae were allowed to adhere to Petri dishes overnight at 18°C. The adherent 
cells were removed by the addition of 1000 [tL Hanks balanced salt solution with 
Arypsin and EDTA (Appendix 1), washed, centrifuged and concentrated. Live 
amoeba counts were determined using a haemocytometer (Neubauer, BS 748). 
Three replicate counts were made with 18 large squares counted per replicate. The 
isolation obtained 2 500 000 amoeba delivering a final concentration of 
approximately 300 cells L' i per system. Individual aliquots were placed into the 
three system sumps and foam fractionators were turned off. 
4.3.3 Feed preparation 
Commercially available 4 mm Atlantic Salmon Grower LE pellet (SkrettingTM, 
Hobart, Australia) was used for all treatments. Feed was prepared as needed in 
100 g batches and stored at 4°C. The control with oil was prepared by moistening 
feed with 7 mL distilled water, then evenly coating with 5 mL of fish oil by shaking 
food in a plastic bag until well coated. The food was air dried for 24 h before being 
placed into an airtight container and held at 4°C. This same procedure was used to 
prepare the bithionol diet with the inclusion of 2.5 mg of bithionol (Sigma-Aldrich 
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Pty. Ltd, Castle Hill, Australia) which was combined with the fish oil prior to 
coating the moistened pellet. 
4.3.4 Data Collection 
Total tank mass was obtained weekly using a minimum of ten fish per tank. Fish 
were sampled (two fish per tank) at transfer, 14 days prior to infection and then 
twice weekly for 28 days. For each fish, mass and fork length data was recorded as 
well as gross and histological examination of internal organs for any signs of 
toxicity. The gross gill score data were recorded using categories seen in Table 
4.3-1 (Adams and Nowak, 2003). Fish were anaesthetised or euthanized using clove 
oil at a concentration of 0.02% w/v and all procedures were conducted in 
accordance with the Australian code of practice for care and use of animals for 
scientific purposes under the guidance of the Uni \iersity of Tasmania Animal 
Ethics. Specific growth rate (SGR) and Fulton's condition factor (K) were 
calculated using equation 1 and 2. Fulton's condition factor was calculated using 
the individually sampled fish. The SGR was calculated using the average fish mass 
for each tank for Day -14 and Day 0 and then from Day 0 to the Day where there 
were a median number of 15 fish left. This was done due to the variation in fish 
numbers within tanks at the culmination of the trial. 
SGR 
Ln weight (g) 2 — Ln weight (g),  
x100= 
A time 
weight(g)  K =[ 	 1(100 
length x length x length (cm) 
[1] 
[2] 
- 79 - 
Chapter Four 	 Efficacy of bithionol as an oral treatment 
Table 4.3-1. Scoring scheme for gross signs of amoebic gill disease on Atlantic 
salmon modified from Adams and Nowak (2003). 
Infection Level 
	
Score 	Number of affected holobranchs 
Clear 	 0 	 0 
Light 	 1 	 <2 
Moderate 	 2 	 2-5 
Heavy 	 3 	 >5 
4.3.5 Histology 
The left gill basket was excised, rinsed gently in 0.2 um filtered seawater, fixed in 
seawater Davidson's fixative and the liver, kidney, and muscle were fixed in 10% 
neutrally buffered formalin for 24 h, and then transferred to 70% ethanol. The 
second left anterior hemibranch was removed, along with a small section of liver, 
kidney and muscle, dehydrated, embedded in paraffin wax, sectioned at 5 um, and 
stained with haematoxylin and eosin (H & E). The sections were viewed under a 
light microscope (Olympus) at X100 to X400 magnifications. The number of 
filaments exhibiting AGD lesions were counted and expressed as proportions of the 
total number of filaments in each section (Parsons etal., 2001a). A filament was 
counted only when the central venous sinus was visible in at least two-thirds of the 
filament and lamellae were of equal length bilaterally present to near the tip of the 
filament (Speare et al., 1997). 
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4.3.6 Statistical Analysis 
Statistical analysis was conducted using SPSS for Windows ® (version 11.5). A 
mixed model analysis of variance (ANOVA) containing factorial and nested terms 
was used to determine differences with treatment and day sampled as fixed factors 
and tank as a random factor. There was no difference determined between the oil 
coated control and the plain control diets with respect to the AGD variables; 
therefore the control treatments were combined and compared to the bithionol 
treatment. The interaction between day sampled and treatment was examined first; 
if not significant, then treatment and day sampled could be examined individually. 
If a significant difference was identified among treatments and/or days sampled, 
then a Tukey's post hoc test was used to identify where the differences occurred. 
Homogeneity was determined using a residual plot and Levene's test. A result was 
considered significant if p < 0.05 and results are presented as a mean ± SEM. 
Relative percent reduction (RPR) was calculated for percent lesioned gill filaments 
using the following equation: 
number of percent lesioned gill filaments in treated group 
RPR = 1 
	
	  x100 
number of percent lesioned gill filaments in control group 
4.4 	Results 
At the culmination of the trial all fish had exhibited signs of AGD. As expected, 
there were no significant differences between gross gill scores and percent lesioned 
gill filaments for the plain and oil control feeds; therefore they were combined. 
There appeared to be no problems associated with palatability as feed was eaten 
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across all treatments and mortalities were observed across all treatments. No 
toxicity problems were observed based on gross examination of internal organs and 
histological examination of the kidney, liver and muscle (histology not shown). 
Bithionol treated fish exhibited significantly reduced lesioned gill filaments over 
the entire trial when compared to control fish (Fig 4.4-1a). Lesions were first 
observed on Day 7 in control groups compared to Day 10 in the bithionol group and 
percent lesioned gill filaments increased throughout the trial. Significant reductions 
in percent lesioned gill filaments were first observed between bithionol treated fish 
and control fish on Day 10 (F2,15= 50.101, p <0.001), and continued to the 
culmination of the trial at Day 28 (F2,15= 41.099, p <0.001) post-Neoparamoeba 
spp. exposure. Bithionol was successful in delaying the onset of percent lesioned 
gill filaments seen typically with AGD by 53% when compared to the control diets 
at the culmination of the trial (Day 28) post-exposure. A similar result was seen 
with the gross gill score, where on Day 28 controls had a mean gross gill score of 
two, which was significantly higher compared to bithionol treated fish exhibiting a 
mean gross gill score of one (F2,15= 25, p <0.001, Fig 4.4-1b). However, there 
were no differences observed in gross gill score on any other day throughout the 
trial. 
There appeared to be no palatability problems associated with bithionol when fed 
at 25 mg kg' feed. Weekly feed intake in all treatment groups was determined 
significantly different over the duration of the trial (F2,6= 85.372, p = <0.001) post-
Neoparamoeba spp. exposure (Fig 4.4-2a). As the trial progressed the feed intake 
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began to decrease across all treatments particularly from Day 14 onwards for the 
control treatments and Day 21 onwards for the bithionol treatment, which coincided 
with heavier parasite load. However, there were no differences observed in the 
mean tank biomass mass of the fish across all treatments throughout the trial (F2 ,6 = 
0.348, p = 0.792 Fig 4.4-2b ) or SGR (F 1 , 1 8 = 0.099, p < 0.001, Table 4.4-1) but a 
difference in K was observed (F2, 1 5= 5.708, p = 0.014, Table 4.4-1). 
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Fig 4.4-1. (a) percent lesioned gill filaments and (b) gross gill score for Atlantic 
salmon with amoebic gill disease (AGD) when fed either control feed (solid line) 
(n = 12) or bithionol at 25 mg kg-1 feed (broken line) (n = 6). No error bars 
indicate that all replicates exhibited the same value. Values are expressed as mean 
± SEM. Letters denote significant differences among treatments at that sampling 
time (p <0.05). 
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-14 -7 0 7 	14 21 28 
Day from Neoparamoeba sp. exposure 
Days from Neoparamoeba spp. exposure 
Fig 4.4-2. (a) weekly tank feed intake (n = 3) and (b) weekly tank biomass (n = 3) 
for Atlantic salmon exposed to Neoparamoeba spp. when fed either commercial 
feed (closed circles), oil-coated commercial feed (open circles) or bithionol at 25 
mg kg -I feed (broken line and open squares). Values are expressed as mean ± 
SEM. Letters denote significant differences among treatments over the trial 
duration (p < 0.05). 
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Table 4.4-1. Mean tank specific growth rate (SGR) (n = 3) and individual fish condition factor, (K) (n = 6) for plain control, oil control and 
bithionol treated Atlantic salmon feed from Day -14 to 0 and Day 0 to Day 10 Neoparamoeba spp. exposure. Values are mean ± SEM. Asterisks 
indicate significant difference between treatments within each time point (p<0.05). 
Treatment 
Day -14 to 0 	 Day 0 to Day 10 
Plain Oil Bithionol Plain Oil Bithionol 
SGR (% day-I ) 1.36 1.59 1.25 -0.11 -0.41 -0.12 
± 0.11 ± 0.25 ± 0.20 ± 0.15 ± 0.23 ± 0.10 
K (%) 0.89 0.81 0.84 1.04 0.97 1.16* 
± 0.07 ± 0.04 ± 0.01 ± 0.04 ± 0.04 ± 0.02 
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4.5 	Discussion 
During a laboratory infection in which bithionol was orally administered at 25 mg 
kg-1 feed, the intensity of AGD pathology was significantly delayed and reduced 
compared to the control fish. A 53% relative reduction in percent lesioned gill 
filaments was observed when compared to the controls. Furthermore, gross gill 
scores were halved in the salmon treated with bithionol suggesting that this drug 
may be an effective therapeutic for AGD. This trial examined bithionol efficacy 
during the first four weeks of a Neoparamoeba spp. challenge and differences in gill 
score were only observed on the last day. Due to stocking density limitations, it was 
not possible to continue the trial further; however, it would be advantageous in 
future studies to continue past this time point. Similarly, bithionol was effective 
against the gill monogenean parasite Microcotyle sebastis infestations in marine 
rockfish, Sebastes schlegeli, resulting in a 66-93% reduction in parasite numbers 
when used at 1.25 g kg- feed for 10-20 days (Kim and Choi, 1998). In contrast, 
bithionol was reported to be ineffective as a treatment of Hexamita salmonis, 
Gyrodactylus sp., and Ichthyobodo necator infestations in rainbow trout, 
Oncorhynchus mykiss (Tojo and Santamarina, 1998a; b; c); however, classification 
of effectiveness in these experiments was complete elimination of the parasites. 
Bithionol when fed at 40 g kg-I feed for 10 days did not achieve complete 
elimination of the parasites but produced an 80% reduction in H. salmonis whilst 
Gyrodactylus sp. and I. necator numbers were reduced from a high to low intensity. 
Whilst complete elimination of Neoparamoeba spp. would be welcomed, a 
treatment that is comparable in efficacy to bath treatment with freshwater and less 
labour intensive and more cost effective is a more realistic option, at least initially. 
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Bithionol has a melting point of 188°C; therefore it is possible that it could 
withstand the heat extrusion process so that it could be included at the feed 
preparation stage and, based upon the cost of bithionol, it would cost approximately 
$120 tonne -I (Sigma-Aldrich, 2006). 
The standard laboratory-induced AGD infections using the isolation method 
described by Morrison et al. (2004) consistently induces AGD in Atlantic salmon. 
The severity of AGD in the laboratory is influenced by the amoeba challenge 
concentration and temperature (Zilberg et al., 2001). Therefore, aggressive 
laboratory-induced AGD infections used in this study exhibit an increased rate of 
infection when compared to clinical AGD outbreaks on commercial salmon farms 
where there are less severe infection rates. Under laboratory conditions, there is no 
administration of freshwater baths and water is recirculated creating the potential 
for the continuous colonisation of the gills. Hence, differences observed between 
the two infection types are due to amoeba concentration and optimal laboratory 
conditions for AGD (Roberts and Powell, 2005). Fish affected with AGD on 
commercial farm field trials have been identified as having between 5% percent 
lesioned filaments coinciding with a freshwater bath and 10-20% 18 weeks post sea 
transfer (Adams and Nowak, 2003; Roberts and Powell, 2003a). This trial showed 
differences in the intensity of AGD pathology when fish were fed bithionol in an 
aggressive laboratory infection, warranting further investigation into the potential 
for oral administration of bithionol on commercial farms where AGD infections are 
typically chronic (Roberts and Powell, 2005). Further investigation of bithionol 
would include but not be limited to examining the pharmacokinetics and 
- 88 - 
Chapter Four 	 Efficacy of bithionol as an oral treatment 
bioavailability. The pharmacokinetics of bithionol regarding absorption, 
distribution, metabolism and excretion are not known within fish and are necessary 
for correct administration of bithionol. 
Other compounds that have been examined as an in-feed treatment for AGD 
include the mucolytic drug L-cysteine ethyl ester (LCEE) (Roberts and Powell, 
2005). Furthermore, the oral administration of nutritional supplements Aquacite TM 
and BetabecTM  has been examined as an alternative treatment strategy (Mlynarski, 
et al., unpublished data). It was identified that the progression of AGD when 
salmon were exposed to cohabitation-induced, aggressive laboratory infection was 
significantly delayed when LCEE was orally administered at 52.7 mg LCEE 
fish di over two weeks. Treated fish had approximately 50% less lesioned gill 
filaments than the control fish three days post-infection. However, there were 
palatability issues, in that the Medicated feed intake was approximately 65% of the 
control feed (Roberts and Powell, 2005). AquaciteTM and BetabecTm nutritional 
supplements in a semi-commercial field trial were found to increase growth rate and 
maintain feed intake and conversion ratios when compared to control. Furthermore, 
the nutritional supplement exhibited a reduction in mortality and a delay in onset of 
AGD lesions (Mlynarski, et al., unpublished data). 
No signs of toxicity were observed when AGD-affected Atlantic salmon were fed 
bithionol at 25 mg kg -I feed c1-1 for 40 days. Similarly, no signs of toxicity were 
observed when bithionol was fed at 40 g kg -1 feed di over 10 days to rainbow trout 
with either H salmonis, Gyrodactylus sp., or I. necator infestations (Tojo and 
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Santamarina, 1998a; b; c). However, in contrast, bithionol exhibited signs of 
toxicity when used to treat M. sebastis infestations in marine rockfish at 1.25 g kg -I 
feed c1 1 for 10-20 days (Kim and Choi, 1998). 
No problems were associated with the palatability of bithionol medicated feed, 
with mean bithionol consumption over the entire trial greater than both the oil and 
plain controls. As the trial progressed the feed intake observed across all treatments 
began to decrease particularly from Day 14 onwards for the control treatments and 
Day 21 onwards for the bithionol treatment, which coincides with heavier parasite 
load. There was however, no difference between treatments when examining 
specific growth rate, this could be due to the small sample size (n = 3) and the 
considerable amount of variation. In future studies it would be advantageous to 
examine SGR using average mass of individually sampled fish as opposed to tank 
average this may aid in comparing data. Conversely, fish fed bithionol exhibited a 
higher condition factor on Day 28 post exposure compared to both control 
treatments. 
4.6 	Conclusion 
Bithionol exhibited potential as an oral treatment for AGD at 25 mg kg -I feed 
when administered for two weeks prior to Neoparamoeba spp. exposure and 4 
weeks following exposure. A reduction in percent lesioned gill filaments and gross 
gill score was achieved over the trial period. Furthermore, bithionol exhibited 
higher feed consumption throughout the study compared to plain and oil coated 
commercial diet and a reduction in mortalities. Further investigation of bithionol as 
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an in-feed treatment for AGD is warranted, including examining the effect of 
prophylactic and therapeutic treatments, running a similar experiment for a longer 
period of time to obtain more growth data, examining the effect of pulse feeding, or 
conducting trials under more realistic field conditions with lower exposure doses 
and freshwater baths. 
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AGD 
Renee L. Florent, Joy A. Becker, Mark D. Powell. 
5.1 	Abstract 
This study examined the efficacy of bithionol as a prophylactic or therapeutic oral 
treatment for Atlantic salmon, Salmo salar, affected by amoebic gill disease 
(AGD). Furthermore, it explored the interaction of bithionol oral therapy with the 
current standard treatment (a freshwater bath for at least 3 h). The efficacy of three 
feeds was determined in the trial by feeding AGD-affected Atlantic salmon at 1% 
body weight (BW) day -I either oil coated commercial feed (control) or prophylactic 
and therapeutic bithionol at 25 mg kg' feed. Feeding commenced two weeks prior 
to exposure to Neoparamoeba spp. at 300 cells L1 and continued for 49 days post 
exposure. Bithionol, when fed as a two week prophylactic or therapeutic treatment 
at 25 mg kg-I feed, delayed the onset of AGD pathology and reduced the percentage 
of gill filaments with lesions. Administration of a 3 h freshwater bath at 28 days 
post-exposure significantly reduced amoebae numbers to a similar level across all 
treatments. In contrast, gross gill score and percent lesioned filaments were reduced 
to different extents, the control having a significantly higher score than both 
bithionol treatments. Following the freshwater bath, clinical signs of AGD 
increased at a similar level across all treatments, albeit controls were significantly 
higher than the bithionol treatments immediately following freshwater treatment. 
This study demonstrated that bithionol at 25 mg kg' feed, when fed as a two week 
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prophylactic or a therapeutic treatment, delayed and reduced the intensity of AGD 
pathology and warrants further investigation as a treatment for AGD-affected 
Atlantic salmon. 
5.2 	Introduction 
Disease has numerous negative impacts on fish and aquaculture production, 
including reduced feed efficiency (Hedrick, 1998), impaired growth (Hedrick, 
1998) and often death (Bakke and Harris, 1998). This in turn represents a direct loss 
of investment in feed, labour and stock to the farmer (Rabago-Castro et al., 2006). 
When examining commercial farming of food fish, many bacterial, viral, fungal and 
parasitic pathogens have been recognised, not only in Tasmania but worldwide 
(Schmahl etal., 1989; Stoffregen etal., 1996). In the control of these pathogens, 
particularly external parasites of farmed marine fish, chemical treatments are 
common (Powell and Clark, 2004). However, since the turn of the 21' century there 
have been few new chemotherapeutic agents approved for use in aquaculture for 
several reasons, including concerns regarding environmental impact, cost and 
residues in food fish and the fact that it is often a limited market for drug companies 
(Shao, 2001). The continual improvement and development of cost-effective fish-
husbandry practices, including efficacious chemotherapeutants, is critical for the 
success of the aquaculture industry and increased production (Stoffregen et al., 
1996). 
Chemotherapeutants provide effective methods of preventing (prophylactic 
treatments) and controlling (therapeutic treatments) fish mortality and disease, and 
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are applied either via bath or oral administration (Armstrong, 1994; Howe et al., 
1999). Many fish farmers from North America (Thorburn and Moccia, 1993), Asia 
(Tonguthai, 1997), Europe (Alderman, 2002) and Africa (Hecht and Endemann, 
1998) resort to the use of prophylactic treatments to aid in the prevention of 
epidemics. Several therapeutic agents have been examined for both prophylactic 
and therapeutic treatment of ectoparasitic infections; these include but are not 
limited to a formalin bath to treat trichodinads and monogeneans (Noga, 2000), 
chloramine-T for infections in salmon (Harris et al., 2004), hydrogen peroxide for 
monogeneans (Mansell et al., 2005), emamectin benzoate for sea lice (Ramstad et 
al., 2002; Treasurer etal., 2002), and bithionol as a bath treatment for salmonid 
parasites including .Gyrodactylus sp., khthyobodo necator (Santamarina etal., 
1991; Tojo et al., 1994b). More recently, bithionol has shown efficacy for the 
treatment of Neoparamoeba spp. (Florent etal., 2007a; b). 
Until recently the presumptive causative agents of AGD were thought to be two 
amphizoic amoebae Neoparamoeba pemaquidensis (Kent et al., 1988; Roubal et 
aL, 1989) and N. branchiphila (Dykova etal., 2005). However, attempts to 
determine the pathogenicity of either species by re-infecting fish using clonal, 
cultured, gill-derived strains have been universally unsuccessful (Kent etal., 1988; 
Howard, 2001; Morrison etal., 2005). Neoparamoeba perurans is a protozoan 
parasite that was recently described as the predominant aetiological agent of AGD 
of Atlantic salmon cultured in Tasmania, Australia (Young etal., 2007). Amoebic 
gill disease has been diagnosed in a number of fish species cultured in the marine 
environment worldwide (Nowak etal., 2002). It is a significant problem for 
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Australian salmon aquaculture with the disease accounting for 10-20% of the gross 
cost of production (Munday et al., 2001; Nowak et al., 2007). This is due not only 
to the cost of treating and managing the disease, but also to loss of fish condition 
and production costs. The mitigation of AGD in Tasmania is mostly due to 
freshwater bathing which was first recommended by Foster and Percival (1988). 
However, the efficacy is variable and has notably become increasingly less effective 
(Parsons etal., 2001a; Powell and Clark, 2003); hence there is a push to identify 
alternative, more cost-effective and less labour intensive treatments, preferably 
delivered in-feed. 
A large variety of antimicrobials, disinfectants and detergents have been 
examined both in vitro on isolated gill amoebae and in vivo as both bath and feed 
additives for AGD mitigation. Attempts to identify potential chemotherapeutic 
agents have been limited due to either lack of direct efficacy on the parasite, target 
fish toxicity or the cost of treatment (Alexander, 1991; Howard and Carson, 1994). 
Toxicity of several compounds to Neoparamoeba spp. has been examined in vitro 
including levamisole (Howard and Carson, 1995), chlorine dioxide, chloramine-T, 
hydrogen peroxide (Powell et al., 2003; Powell and Clark, 2003), amprolium, 
albendazole, toltrazuril and bithionol (Powell etal., 2003), all with low to moderate 
success. Howard and Carson (1994) reported that levamisole at concentrations > 10 
ppm in vitro were lethal to N. pemaquidensis, and chloramine-T concentrations of 
25 and 50 ppm effectively reduced amoeba numbers after 2 h (Powell and Clark, 
2003).-Powell etal. (2003) found amprolium at 1 mg 1.:1 and bithionol at 1 and 10 
mg Li to be amoebicidal in vitro. Compounds that have been examined as in-feed 
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treatment for AGD include the mucolytic compound L-cysteine ethyl ester (LCEE), 
which delayed progression of pathology associated with AGD and reduced percent 
lesioned gill filaments by approximately 50% relative to the control when fed at 
52.7 mg kg1 fish day-I for 2 weeks (Roberts and Powell, 2005). However, it was 
not commercially viable and other mucolytic agents (N-acetyl cysteine) were not 
efficacious (Powell et cd., 2007). Bithionol, a phenolic compound reported as 
effective against bacteria, moulds and yeast (Kim and Choi, 1998), was found to be 
both non-toxic and efficacious; during a laboratory infection in which bithionol was 
prophylactically orally administered at 25 mg kg I feed, the intensity of AGD 
pathology was significantly delayed and reduced compared to the control fish 
(Florent et al., 2007b). 
The present study aimed to examine the interaction of bithionol oral therapy with 
the standard treatment (a freshwater bath for at least 3 h) and to examine the rate of 
re-infection. The role of alternative disease management strategies in controlling 
• AGD is yet to be fully explored, but has the possibility to provide significant 
economic advantages to the industry. Currently, it is difficult to omit freshwater 
bathing and perhaps the best likelihood of success if through a multi-faceted 
approach to AGD management. 
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5.3 	Materials and Methods 
5.3.1 Fish husbandry and maintenance 
Atlantic salmon, Salmo salar, (AS) diploid mixed-sex spring smolts, with a mass 
of 130.4 ± 9.8 g (N = 396) were obtained from SALTAS salmon hatchery 
(Wayatinah, Tasmania, Australia). Fish were maintained at the University of 
Tasmania Aquaculture Centre for a minimum of three weeks prior to 
experimentation. Salmon were acclimated to seawater (35%0, 1 p.m filtered, 
temperature of 16.0 ± 0.8°C) over 14 days in one 3000 L Rathbum tank with 
recirculated water and an individual biofilter system. The tank received constant 
aeration and oxygen levels were monitored daily using a Handy Gamma Oxy Guard 
(Birkerod, Denmark), with dissolved oxygen levels of 92 ± 0.4% saturation. Fish 
were fed a commercially available 3 mm Atlantic Salmon Grower LE pellet 
(SkrettingTM, Hobart, Australia) twice daily to satiation throughout the seawater 
acclimation period. 
5.3.2 Experimental design and challenge method 
Three hundred and ninety-six Atlantic salmon were equally and randomly 
allocated into nine tanks at a stocking density of 9.9 ± 0.3 g L -1 . The tanks were in 
three separate ultraviolet light-treated seawater re-circulating systems, each 
consisting of three 590 L tanks, a 500 L header tank, and a 500 L sump providing a 
total volume of 2770 L. All tanks received constant aeration with water temperature 
and oxygen levels monitored daily. Fish were allowed to habituate to their 
respective systems for one week, with system conditions maintained on a 
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photoperiod of 12 h each of light and dark, with water temperature 17.0 ± 0.6 °C, 
and pH 8.08 ± 0.25, and were fed to satiation using a 3 mm commercial feed prior 
to commencing experimental procedures. Following conditioning, each tank was 
randomly allocated a treatment. The treatment groups were referred to as (1) the 
control, an oil coated commercial diet, (2) prophylactic, a bithionol treated diet at 
25 mg kg' feed, fed for 14 days prior to exposure and (3) therapeutic bithionol fed 
at the presentation of clinical signs. This dose was chosen based on previous work, 
which showed bithionol to be effective when administered orally at 25 mg kg -I feed 
(Florent etal., 2007b). Fish were fed at a maximum of 1% body weight (BW) day -I 
equally dispersed over 12 h throughout the entire study, with feed intake recorded 
daily. Daily feed intake was determined by subtracting the weight of uneaten feed 
from the amount of feed weighed out for that day. Weekly feed intake was 
determined as a percent of the fish biomass by dividing the average tank feed intake 
for the week by the average tank biomass and multiplying by 100 to obtain the 
weekly mean feed intake as a percent body weight. Weight checks of a minimum of 
half the fish per tank were conducted weekly to determine feed intake as percent 
body weight. All treatments were fed for 14 days prior to exposure to 
Neoparamoeba spp., with the control and therapeutic tanks receiving the control 
diet and feeding continued for a further 49 days post-exposure with respective 
treatments. 
Fish were experimentally exposed to Neoparamoeba spp. which were isolated 
according to Morrison et al. (2004). Briefly, eight donor Atlantic salmon were 
obtained from the University of Tasmania Aquaculture Centre experimental AGD 
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infection tank. Gill baskets were excised from moribund salmon centrifuged at 400 
g for 2 min in distilled water and rinsed with seawater three times to dislodge 
amoebae from the gills. Amoebae in seawater were allowed to adhere to Petri 
dishes for approximately 2 h at 18°C. Plates were washed with clean seawater and 
approximately 20 mL of seawater was added. Amoebae were allowed to adhere to 
Petri dishes overnight at 18°C. The adherent cells were removed by the addition of 
10004 Hanks balanced salt solution with trypsin and EDTA (Appendix 1), 
washed, centrifuged at 400 g for 5 min and concentrated. Live amoeba counts were 
determined using a haemocytometer (Neubauer, BS 748). Three replicate counts 
were made with 18 large squares counted per replicate. The isolation delivered 2 
500 000 amoeba at a final concentration of approximately 300 cells L -I per system. 
Individual aliquots were placed into the three system sumps. The ultra-violet light 
units and foam fractionators were turned off immediately following exposure. Once 
gross lesions were observed and therapeutic treatment commenced all of the ultra-
violet light units and foam fractionators were switched on and remained activated 
for the duration of the study. 
5.3.3 Bath Administration 
Following 28 days of exposure to Neoparamoeba spp., a 3 h freshwater 
(municipal source, 17.0°C, pH 7.2, treated with sodium thiosulphate at 0.005 mg L -I 
to remove chlorine) bath was administered. Each tank of fish was placed into 
separate 100 L plastic containers at a stocking density of 30 g 	Tubs received 
constant aeration with oxygen levels monitored every 10 min and maintained at 
110% saturation using oxygen, if required. Temperature, salinity, pH, ammonia, 
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nitrate and nitrite were measured hourly for the duration of the bath. Following the 
3 h bath fish were returned to their original tank. 
5.3.4 Feed preparation 
Commercially available 3 mm Atlantic Salmon Grower LE pellets (SkrettingTM, 
Hobart, Australia) were used for all treatments. Feed was prepared as needed in 1 
kg batches and stored at 4°C. The control diet was prepared by moistening feed with 
60 mL distilled water, then evenly coating with 30 mL of fish oil by shaking the 
feed in a plastic bag until well coated. The feed was air dried for 24 h on a tray in a 
force-draught fume hood (Forma Scientific, Ohio, USA), before being placed in an 
airtight container and stored at 4°C. This same procedure was used to prepare the 
bithionol diets with the inclusion of 25 mg of bithionol (Sigma-Aldrich Pty. Ltd, 
Castle Hill, Australia) which was combined with the fish oil prior to coating the 
moistened pellet. 
5.3.5 Data Collection 
Total tank mass of fish was obtained weekly, using a minimum of half the fish per 
tank. Fish were sampled (four fish per tank for 0-3 weeks post-exposure (PE) (n=12 
per treatment) and three fish per tank from 4-7 weeks PE, (n=9 per treatment), 14 
days prior to exposure, at the point of exposure, weekly for seven weeks and pre-
and post-freshwater bath. For each fish, mass and fork length data were recorded, as 
well as gross examination of internal organs for any signs of toxicity. The gross gill 
score data were recorded using categories seen in Table 5.3-1(Adams and Nowak, 
2003). Immediately prior to and following the freshwater bath treatment, 
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Neoparamoeba spp. were re-isolated from the gills using the technique of Florent et 
al. (2007a) modified from Howard and Carson (1995) and Powell and Clark (2003). 
Briefly, the right gill basket was excised and rinsed gently in 0.2 p.m filtered 
seawater and individual arches were scraped with a bacterial spreader to remove 
mucus. Mucus was collected in individual 50 mL centrifuge tubes and re-suspended 
in sterile seawater up to 10 mL. A 100 p.1_, aliquot of mucus-amoeba suspension was 
sampled and stained with 0.05% trypan blue viability stain at a dilution of 1:1. Live 
amoeba counts were determined using a haemocytometer. Three replicate counts 
were made with 18 large squares counted per replicate. The total number of live 
amoebae per fish was calculated and divided by the natural log of the fish mass to 
account for scaling differences in gill surface area with fish of different mass 
(Palzenberger and Pohla, 1992). In all cases, fish were euthanized or anaesthetised 
using clove oil at a concentration of 0.02% w/v. All procedures were conducted in 
accordance with the Australian Code of Practice for the care and use of animals for 
scientific research (7 th edition), under administration of the University of Tasmania 
Animal Ethics Committee. Specific growth rates (SGR), Fulton's condition factor 
(K) and feed conversion ratio (FCR) were calculated using equation 1, 2 and 3, 
respectively. The K was calculated using the individual lethal fish samples and the 
SGR and FCR were calculated weekly using the average fish mass and average feed 
intake for each tank. 
Ln weight (g) 2 — Ln weight (g),  
SGR — 	 x100 
A time [1] 
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weight(g)  
K = [ 	 ix 100 
length x length x length (cm) 
FCR 
average feed intake (g) 
= 
average fish biomass 2 (g) — average fish biomass, (g) 
Table 5.3-1. Scoring scheme for gross signs of amoebic gill . disease on Atlantic 
salmon modified from Adams and Nowak (2003). 
Infection Level 
	
Score 	Number of affected holobranchs 
Clear 	 0 	 0 . 
Light 	 1 	 <2 
• Moderate 	 • 2 	 2-5 
Heavy 	 3 	 >5 
5.4 Histology 
The left gill basket was excised, rinsed gently in 0.2 pm filtered seawater, fixed in 
seawater Davidson's fixative and the liver, kidney, and muscle were fixed in 10% 
neutrally buffered freshwater formalin for 24 h, and transferred to 70% ethanol. The 
second left anterior arch was removed, along with a small section of liver, kidney 
and muscle, dehydrated, embedded in paraffin wax, sectioned at 5 pm, and stained 
with haematoxylin and eosin (H & E). The sections were viewed under a light 
[2] 
[3] 
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microscope (Olympus, Hamburg, Germany) at X100 to X400 magnifications. The 
number of filaments exhibiting AGD lesions were counted and expressed as 
proportions of the total number of filaments in each section. A filament was counted 
only when the central venous sinus was visible in at least two-thirds of the filament 
•I 
and the lamellae were of equal length bilaterally present to near the tip of the 
filament (Speare et al., 1997). The size of the AGD lesions was recorded with 
lesion size determined by counting the number of hyperplastic interlamellar units 
within each lesion as described in•Admas & Nowak (2001). A Leica DC300F 
digital camera (Leica Microsystems, Wetzlar, Germany) C-mounted to a light 
microscope (Olympus, Hamburg, Germany) was used for image capture. Liver, 
kidney and muscle tissue sections were examined for pathological changes 
including epithelial separation, aneurisms, change in pavement cells, chloride cells, 
hyperplasia, and inflammation (Mallatt, 1985; Takashima and Hibiya, 1994). 
5.4.1 Statistical Analyses 
Statistical analysis was conducted using SPSS for Windows (version 11.5). A 
mixed model analysis of variance (ANOVA) containing factorial and nested terms 
was used to determine differences, with treatment and day sampled as fixed factor 
and tank as a random factor. The interaction between day sampled and treatment 
was examined first, and if this was not significant then treatment and day sampled 
were examined individually. If a significant difference was identified among 
treatments and/or days sampled then a Tukey's post hoc test was used to identify 
where the differences occurred. Differences among treatments of the tank variables, 
including feed intake, FCR and SGR, were analysed using a repeated measures 
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ANOVA, then a Tukey's post hoc test was used to identify where the differences 
occurred. Homogeneity was determined using a residual plot and Levene's test. A 
result was considered significant if p < 0.05 and results are presented as a mean ± 
SEM. Relative percent reduction (RPR) was calculated for percent lesioned gill 
filaments using equation 4. 
RPR = 	
number of percent lesioned gill filaments in treated group x100 [4] 1 
number of percent lesioned gill filaments in control group 
5.5 	Results 
There were no differences observed in feed intake among treatments throughout 
the duration of the trial (F2,6 = 0.793, p = 0.495, Fig 5.5-1). As the trial progressed, 
the feed intake began to decrease across all treatments particularly from Day 14 
onwards, which coincided with heavier parasite load. On Day -7 and 21 there was a 
sudden decrease in feed intake which was correlated with an increase in water 
temperature (r = 0.359, n = 81, p = 0.001). As expected, considering there were no 
differences between feed intakes, no differences in the mean condition factor (K) 
(F2,6 = 0.209, p = 0.817, Table 5.5-1) specific growth rate (SGR) (F2,6= 4.134, p = 
0.0, Table 5.5-1) or feed conversion ratio (FCR) (F2,6= 1.028, p = 0.413, Table 
5.5-1) were observed across all treatments throughout the trial. 
- 105 - 
Chapter Five 	Further development of bithionol therapy as a treatment for AGD 
0.4 	 
-14 -7 	0 	'7 	14 21 28 35 42 49 
Days from Neoparamoeba spp. exposure 
Fig 5.5-1. Mean (± SEM) weekly tank feed intake (n = 3) for Atlantic salmon 
exposed to Neoparamoeba spp. when fed either control feed (dotted line open 
circle), prophylactic bithionol at 25 mg kg -I feed (solid line closed circle) or 
therapeutic bithionol at 25 mg kg' feed (solid line open square). No error bars 
indicate that all replicates within a treatment exhibited the same value. The 
vertical broken line indicates administration of a 3 h freshwater bath. 
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Table 5.5-1. Tank specific growth rate (SGR) (n = 3), individual fish condition factor (K) (n = 9) and tank feed conversion ratio (n = 3) for 
Atlantic salmon fed either oil coated commercial feed (C), prophylactic (PB) or therapeutic (TB) bithionol at 25 mg kg -I feed from Day -14 to 0, 
Day 0 to 14, Day 14 to 28 and Day 28 to 42 from Neoparamoeba spp. exposure. All values are expressed as mean ± SEM. 
Treatment 
Day -14 to 0 Day 0 to 14 
PB TB PB TB 
SGR (% day-I ) 
FCR 
1.14 ± 0.50 
0.86 ± 0.02 
0.19 ± 0.09 
0.72 ± 0.08 
0.81 ± 0.04 
0.18 ± 0.02 
0.53 ± 0.17 
0.85 ± 0.03 
0.30± 0.10 
6.95 ± 3.12 
0.84 ± 0.03 
-0.02 ± 0.25 
10.18 ± 0.01 
0.87 ± 0.03 
0.21 ± 0.01 
10.15 ± 0.07 
0.86 ± 0.03 
0.44 ± 0.24 
Treatment 
Day 14 to 28 Day 28 to 42 
PB TB PB TB 
SGR (% day-1 ) 
FCR 
-1.21 ± 1.99 
0.82 ± 0.04 
0.18 ± 0.11 
0.37 ± 0.29 
0.82 ± 0.05 
5.63 ± 4.85 
-1.33 ± 1.19 
0.76 ± 0.04 
0.02 ± 0.12 
1.77 ± 0.60 
0.80 ± 0.04 
0.13 ± 0.05 
1.41 ± 0.12 
0.84 ± 0.04 
0.12± 0.01 
2.57 ± 1.11 
0.77 ± 0.04 
0.11 ± 0.04 
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At the culmination of the trial all fish had exhibited signs of AGD. There 
appeared to be no problems associated with palatability as feed was eaten across all 
treatments and mortalities were observed across all treatments. No host toxicity was 
observed based on gross examination of internal organs and histological 
examination of the kidney, liver and muscle (histology not shown). 
Fish administered bithionol at 25 mg kg ' 	either prophylactically (14 days 
prior to Neoparamoeba spp. exposure) or therapeutically (upon clinical signs of 
AGD), exhibited significantly reduced clinical signs of AGD including gross gill 
score (F6,36 = 263.628, p < 0.001, Fig 5.5-2a) and percent lesioned gill filaments 
over the entire trial, when compared to control fish (F6,36= 276.011, p <0.001, Fig 
5.5-2b). 'Gross gill score and percent lesioned gill filaments were first observed on 
Day 7 in all treatment groups. From Day 14 onwards both the gross gill score and 
percent lesioned gill filaments increased at a greater rate in the control group 
compared to both bithionol treatments. Significant reductions in percent lesioned 
gill filaments were first observed between bithionol treated fish and control fish on 
Day 14 and continued throughout the duration of the trial (F2,6= 73.035, p <0.001, 
Fig 5.5-2b). Bithionol, when administered either prophylactically or therapeutically, 
was effective in reducing the proportion of lesioned gill filaments by approximately 
30% when compared to the control treatment prior to the freshwater bath 
administered on Day 28 PE. At the culmination of the trial (Day 49 PE) the 
difference observed between both bithionol and control treatments was 
approximately 40% reduction in percent lesions. A similar result was seen with the 
gross gill score, where on Day 28 controls had a mean gross gill score of four. This 
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was significantly higher compared to bithionol treated fish, which exhibited a mean 
gross gill score of 2.8, and this difference continued throughout the trial (F),6= 
21.851, p = 0.002, Fig 5.5-2a). As expected, there were differences with respect to 
time for both gross gill score (F6,36= 263.628, p < 0.001, Fig 5.5-2a) and percent 
lesioned filaments (F6,36 = 276.011, p < 0.001, Fig 5.5-2b) with values increasing 
until the freshwater bath was administered (Day 28 PE), after which values dropped 
to similar levels as seen on Day 14 PE and slowly began to increase until the 
culmination of the trial. Interestingly, the progression of lesion development was 
similar among all treatments following the freshwater bath until the culmination of 
the trial for both gross gill score and percent lesioned gill filaments (Fig 5.5-2a, b). 
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0 	7 	14 21 28 35 42 49 
Days from Neoparamoeba spp. exposure 
0 	7 	14 21 	28 35 42 49 
Days from Neoparamoeba spp. exposure 
Fig 5.5-2. (a) gross gill score and (b) percent lesioned gill filaments for Atlantic 
salmon with amoebic gill disease (AGD) when fed either control feed (dotted line 
open circle), prophylactic bithionol at 25 mg kg-I feed (solid line closed circle) or 
therapeutic bithionol at 25 mg kg -I feed (solid line open square) (n = 12 pre-bath 
or 9 post-bath). All values are expressed as mean ± SEM. No error bars indicate 
that all replicates within a treatment exhibited the same value. The vertical broken 
line indicates administration of a 3 h freshwater bath. Lower and uppercase letters 
denote significant differences among days and treatments, respectively (p < 0.05). 
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When the size of the lesions was examined, both bithionol treatments had 
significantly smaller AGD lesions when compared to the control (R),6= 7.442, p = 
0.024, Fig 5.5-3). A -relative percent reduction in lesion size of approximately 20- 
30% was observed for both bithionol treatments from Day 21 onwards when 
compared to the control treatment. There was a significant difference With respect 
to time when examining lesion size (F6,36= 42.798, p <0.001, Fig 5.5-3), with 
lesion size increasing from Day 0 to Day 21 post-exposure following which it 
reached a plateau for all treatments until the culmination of the trial; interestingly 
lesion size did not decrease or increase following the administration of a 3 h 
freshwater bath. 
Crude amoebae numbers were examined both pre- and post- freshwater bath 
administration with the control treatment exhibiting a greater number of amoebae 
compared to both bithionol treatments prior to the freshwater bath (F2,24 = 11.130, p 
< 0.001,Table 5.5-2). However, following the freshwater bath no difference was 
seen between treatments with crude amoebae numbers reduced to similar levels 
across all treatments (F224 = 1.328, p = 0.284, Table 5.5-2) which was supported by 
the proportional decrease in percent lesioned gill filaments (Fig 5.5-2b). 
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Days from Neoparamoeba spp. exposure 
Fig 5.5-3. Lesion size in inter lamellae units (ILU) for Atlantic salmon with 
amoebic gill disease (AGD) when fed either control feed (dotted line open circle), 
prophylactic bithionol at 25 mg kg -I feed (solid line closed circle) or therapeutic 
bithionol at 25 mg kg' feed (solid line open square) (n = 12 pre-bath or 9 post-
bath). Values are expressed as mean ± SEM. No error bars indicate that all 
replicates within a treatment exhibited the same value. The vertical broken line 
indicates administration of a 3 h freshwater bath. Lower and uppercase letters 
denote significant differences among days and treatments, respectively (p < 0.05). 
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Table 5.5-2. Mean (± SEM) crude amoeba numbers and relative percent reduction pre- and post- 3 h freshwater bath for Atlantic salmon with 
amoebic gill disease (AGD) when fed either control feed, prophylactic bithionol at 25 mg kg -1 feed or therapeutic bithionol at 25 mg kg-1 feed. 
Letters superscripts denote significant differences among treatments (p < 0.05) (n = 9). 
Treatment 
Control 
	
Prophylactic bithionol 	Therapeutic bithionol 
Pre-bath amoeba numbers 
Post-bath amoeba numbers 
228 588± 14638a 
5 259 ± 838c 
149 017 ± 11 
34.81% 
3 733 ±422c 
168b 168 629 ± 11 
26.23% 
4 423 ±623c 
144b 
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5.6 	Discussion 
Atlantic salmon when fed bithionol at 25 mg kg' feed either as a two week 
prophylactic or a therapeutic treatment exhibited significantly delayed and reduced 
clinical signs of AGD compared to controls during a laboratory infection. 
Following 14 days post-exposure, both groups of treated fish had significantly less 
affected filaments than control fish. Prior to the freshwater bath administered on 
Day 28 PE this difference had decreased; however, there were still significantly 
fewer filaments affected than the control fish. A similar result was also seen with 
gross gill score where a difference of approximately one gill score between 
medicated fish and control fish from Day 14 PE onwards. Similarly, bithionol was 
reported effective as a 14 day prophylactic treatment for AGD in Atlantic salmon 
with gross gill score halve and a 53% reduction in percent lesions over 28 days 
(Florent et al., 2007b). Bithionol was effective against the gill monogenean parasite 
Microcotyle sebastis infestations in marine rockfish, Sebastes schlegeli, resulting in 
a 66-93% reduction in parasite numbers when used at 1.25 g kg -I feed for 10-20 
days (Kim and Choi, 1998). In contrast, bithionol was reported to be ineffective as a 
treatment of S. salmonis, Gyrodactylus sp. and I. necator infestations in rainbow 
trout (Tojo and Santamarina, 1998a; b; c); however, in these studies effectiveness 
was defined as a complete elimination of the parasites. Bithionol when fed at 40 g 
kg I feed for 10 days did not achieve complete elimination of the parasites but 
produced an 80% reduction in S. salmonis while Gyrodactylus sp. and I. necator 
numbers were reduced from a high to low intensity (Tojo and Santamarina, 1998a; 
b; c). 
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Crude numbers of viable amoeba pre- and post-bath were found to be higher in 
the control fish compared to the medicated fish pre-bath; however, following the 3 h 
freshwater bath amoeba numbers were reduced to similar levels across all 
treatments with all exhibiting at least a 90% reduction which is similar to levels 
seen in previous studies (Parsons et al., 2001a; Clark et al., 2003). This was not 
seen with gross gill score and percent lesioned filaments which were knocked down 
proportionally rather than to a similar level. However, all treatments had a similar 
percent reduction in lesioned filaments of 60-70% following a freshwater bath and 
gill score was reduced from four to two for the controls and from three to one for 
both bithionol treatments. 
The frequency of freshwater bathing conducted by the Tasmanian Atlantic salmon 
industry is determined by the gross examination of gills. Generally; the trigger for 
initiating a freshwater bath is a gross gill score of two or approximately 25% 
lesioned filaments. So in this study control fish were ready for their first freshwater 
bath around Day 14 PE whereas medicated fish were not at bath level until a week 
later. Additionally, freshwater bathing only removed approximately two thirds of 
the amoebae (Clark etal., 2003), leaving one third of the parasites as a chronic 
persistent infection, which eventually triggers another freshwater bath and the cycle 
is repeated. Nowak et al. (2007) reported that re-infection following a freshwater 
bath occurred although lesions examined histologically immediately post-bath 
exhibited no trophozoites of Neoparamoeba spp. However, several studies have 
shown that reinfection is possible post bath without adding fresh amoebae to the 
seawater (Adams and Nowak, 2001; 2004a; Gross et al., 2004). Hence, following 
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the freshwater bath at Day 28 PE control fish were ready for a second bath at Day 
35 PE compared to medicated feed where bath level was not reached until Day 49 
PE. This indicated that it may be advantageous to use bithionol as a combination 
therapy with the current freshwater mitigation to achieve the best results for 
reduction in clinical signs of AGD. 
Not only did medicated fish exhibit reduced clinical signs of AGD throughout the 
study but the size of AGD lesions was reduced significantly compared to control 
fish. Lesion size seemed to increase until Day 21 after which it reached a plateau for 
all treatments. Interestingly, even following a freshwater bath, lesion size remained 
the same for all treatments. There was a larger variability in lesion size following 
the freshwater bath indicating that lesion size could be altered following the bath. 
However, this could be due to larger lesions reducing in size slightly, whilst smaller 
lesions had a greater rate of reduction. Furthermore, percent lesions decreased, 
creating the possibility that the freshwater bath removed smaller lesions whilst the 
larger lesions remain. Further investigation is warranted to investigate the 
relationship between lesion size and the impact of a freshwater bath. There has been 
minimal published information regarding AGD lesion size. Adams and Nowak 
(2001) examined lesion size in order to describe the distribution and structure of 
AGD lesions and Embar-Gopinath et al. (2005; 2006) examined lesion size with 
respect to the presence of different salmonoid gill bacteria. Lesion size in this study 
was similar to that in Embar-Gopinath et al. (2006) but larger than in Embar-
Gopinath et al. (2005). 
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There were no differences in feed intake with fish in all treatment groups eating a 
similar amount throughout the duration of the study. As the trial progressed the feed 
intake observed across all treatments began to decrease, particularly from Day 14 
onwards, which coincides with heavier parasite load. Furthermore, on Day -7 and 
21 there was a sudden decrease in feed intake. This difference coincided with a 
sudden increase in water temperature, although this was still within the 
physiological range of Atlantic salmon. This is in contrast to previous studies where 
intake of bithionol-treated feed was significantly higher than of control feeds 
(Florent et al., 2007b). This study identified no differences between treatments 
when examining SGR, K and FCR which is similar to previous studies with the 
exception of condition factor where fish fed bithionol at 25 mg kg -1 feed to satiation 
twice daily for 28 days following Neoparamoeba spp. exposure exhibited a higher 
condition factor than control groups (Florent et al., 2007b). It is possible that the 
difference seen between these two studies was due to the different method of 
feeding that is either to satiation twice daily or at 1% BW day -1 . However, fish in 
this study did not to reach the 1% limit regularly, suggesting that there could be 
another factor involved such as time of year or temperature. Further investigations 
would be needed to determine this. 
Bithionol exhibited potential as an oral treatment for AGD at 25 mg kg I feed 
when administered either for 2 weeks prior to (prophylactic) Neoparamoeba spp. 
exposure or at clinical signs of AGD (therapeutic). A reduction in percent lesioned 
gill filaments, lesion size, and gross gill score was achieved over the trial period. 
Bithionol warrants further investigation as a possible in-feed treatment for AGD in 
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Atlantic salmon, especially as a combination therapy with the standard freshwater 
bath treatment. Also, examining the effect of pulse feeding or conducting trials 
under more realistic field conditions with lower exposure doses and freshwater 
baths would be of interest. 
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Throughout this thesis it has be shown that bithionol is toxic to Neoparamoeba 
spp. in vitro and significantly delayed and reduced the intensity of amoebic gill 
disease (AGD) pathology when administered as either a bath or oral treatment. 
Therefore, revealing the potential of using bithionol as either an alternative 
treatment for AGD or as a combination therapy with the current commercial 
freshwater treatment. This indicated that bithionol warrants further investigation as 
a treatment for AGD. The primary aim of this research described in previous 
chapters was to identify an improved method of treatment for AGD caused by 
Neoparamoeba spp. The improved method would have an enhanced efficacy, 
alleviating clinical signs and associated pathology compared to the current 
mitigation strategy of freshwater bathing whilst being economical. This research 
focused primarily on development of an oral treatment for AGD, as producing an 
in-feed treatment would assist in alleviating the release of large amounts of the 
compound into the surrounding water (Findlay et al., 2000) and is less labour 
intensive than bathing fish. The research documented in this thesis successfully 
identified possible improvements or alternative treatments for AGD, involving the 
oral administration of bithionol: 
Herein will discuss the major findings related to the improved or alternative AGD 
treatments, address the economic viability and touch on some environmental issues 
of using such treatments. These past results have been not only necessary for the 
formation of this thesis but have greatly advanced the knowledge surrounding the 
- 120 - 
Chapter Six 	 General Discussion 
treatment of AGD caused by Neoparamoeba spp. and the use of bithionol as a 
treatment for parasites. Most notably, the development of a three-tiered approach to 
identifying drug treatments: Stage I of drug screening would be the development of 
single- and multi-day in vitro toxicity assays and host toxicity procedures; Stage II 
of testing, whereby animals are offered drug-coated feed and subsequently 
experimentally challenged with the parasite to determine fish toxicity and efficacy 
for preventing clinical signs of disease; and Stage III testing involving field trials. 
The research in this thesis has laid the necessary ground work for bithionol and 
bithionol sulphoxide to be progressed to the final stages of treatment investigation 
with a clinical trial. 
A similar drug model has been used to develop the current in-feed treatment for 
sea lice emamectin benzoate as a 0.2 % aquaculture pre-mix identified as Sli ce  ® . A 
great deal of effort has gone into the development of sea lice treatments, including 
bath or dip treatments using dichlorovos, trichlorfon, azamethiphos, cypermethrin, 
carbaryl, pyrethroids and hydrogen peroxide with varying degrees of efficacy 
(Costello, 1993; Roth et al., 1993). Oral doses of ivermectin (Palmer et al., 1987), 
insect growth regulators (Roth et al., 1993) and emamectin benzoate (Stone et al., 
2000) have also been examined. Some of which made it to commercial field trials 
whilst others only to the small scale experimental stages. 
The efficacy and toxicity of SLICE ® (emamectin benzoate) as a treatment for sea 
lice infestations on Atlantic salmon was evaluated through an extensive series of 
clinical studies and field trials (reviewed in Johnson and Margolis, 1993; Roth et 
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al., 1993; MacKinnon, 1997). Initially, emamectin benzoate was used in an 
unformulated state and incorporated in an edible oil for application as a coating on 
pelleted feed. Dose rate determination and dose rate confirmation studies were 
conducted at several locations throughout Scotland. Small field trials were 
conducted in Scotland, Norway, Canada, and Chile. In these field trials, fish were 
fed a commercial feed treated with SLICE ®, 0.2% emamectin benzoate aquaculture 
premix. A daily diet of medicated feed was administered at the recommended dose 
rate of 50 lig kg' biomass day' for 7 consecutive days (Roth etal., 1993; 
MacKinnon, 1997). Commercial field trials were conducted in Canada, Chile, 
Scotland, and Norway. In Norway the efficacy of SLICE ®  was compared to that of 
another in feed treatment, teflubenzuron, a chitin synthesis inhibitor known 
commercially as Ektobann®. Results from four study sites in Norway showed 
SLICE® medicated feed provided better sustained efficacy against sea lice when 
compared to teflubenzuron-treated diets (MacKinnon, 1997). Extensive studies 
have also been conducted examining the effects on the host, the environmental 
impacts and the pharmacokinetics of SLICE ® (MacKinnon, 1993; Chukwudebe et 
aL, 1996; Mushtaq etal., 1996), this enabled the drug emamectin benzoate to 
licensed for use in food fish under the registered trademark of SLICE ®. 
Variability in the effectiveness of freshwater bathing is suggested to be attributed 
1 - to water chemistry, in particular total hardness (mg L CaCO3) (Parsons et al., 
2001a; Parsons etal., 2001b; Clark, 2002; Powell and Clark, 2003; Roberts and 
Powell, 2003a). Freshwater bathing is an environmentally friendly treatment and 
• aids in maintaining the 'clean-green' image of the Australian salmon industry. 
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Roberts and Powell (2003a) reported that in using soft freshwater (19.3 - 37.4 mg I_, - 
CaCO3) delays reinfection and subsequent pathology by at least two weeks 
compared to hard freshwater. Providing the ability to reduce the annual number of 
bath from ten to seven baths per year (Mitchell, 2001; Roberts, 2004) equating to a 
saving of approximately $9.9 million annually. It is possible that with the combined 
use of soft freshwater and an in-feed treatment that the freshwater bath frequency 
could be reduced even further, thus saving more time and money. 
A considerable amount of effort has been placed on identifying possible 
treatments for AGD with varying success. Attempts to identify potential 
chemotherapeutic agents have been limited due to either lack of direct efficacy on 
the parasite, target fish toxicity or the cost of treatment (Alexander, 1991; Howard 
and Carson, 1994). The above model has allowed for a strategic system to screen 
and identify candidate drugs from a large pharmacopeia, whilst maintaining 
effective resource management. Toxicity of several compounds to Neoparamoeba 
spp. has been examined in vitro including levamisole (Howard and Carson, 1995), 
chlorine dioxide, chloramine-T, hydrogen peroxide (Powell et al., 2003; Powell and 
Clark, 2003), amprolium, albendazole, toltrazuril and bithionol (Powell et al., 
2003), all with low to moderate success. Howard and Carson (1994) reported that 
levamisole at concentrations > 10 ppm in vitro were lethal to N. pemaquidensis, and 
chloramine-T concentrations of 25 and 50 ppm effectively reduced amoeba 
numbers after 2 h (Powell and Clark, 2003). 
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Using Stage I of the drug model, it was identified that bithionol was amoebicidal 
at 1 and 10 mg U' (Powell etal., 2003); this was examined further using a greater 
-1 variety of concentrations ranging from 0.1 to 10 mg L (Chapter 2). Bithionol and 
bithionol sulphoxide (a cheaper and supposedly less toxic alternative) were 
successful at reducing amoeba numbers relative to seawater controls. Both were 
-1 toxic to Neoparamoeba spp. at concentrations ranging from 0.1 to 10 mg L over 
72 h. However, freshwater still remained the most toxic with complete mortality of 
Neoparamoeba spp. seen at 48 h. Bithionol was reported to be toxic to the 
trophozoites of the protozoan parasite Giardia lambia at 0.42 and 0.28 mM over 24 
and 72 h, respectively (Takeuchi et al., 1985). Similar results were seen with 
respect to the human protozoan parasite Trichomonas vagina/is where bithionol was 
toxic at 0.42 mM after 24 h (Takeuchi et al., 1985). The toxicity of bithionol in 
vitro was also examined using the human and primate protozoan parasite 
Entamoeba histolytica and found to kill virtually all axenic and polyxenic amoeba 
in 24 h at both 0.42 and 0.28 mM (Takeuchi etal., 1984). 
With regards to Neoparamoeba spp. very few drugs to date have been successful 
at Stage I and thus moved onto Stage II, where animals were offered drug-coated 
feed and subsequently experimentally challenged with the parasite to determine fish 
toxicity and efficacy for preventing clinical signs of disease. Within this thesis, 
Atlantic salmon, Salmo salar, and rainbow trout, Oncorhynchus mykiss, were either 
administered bithionol as a bath treatment or offered bithionol-coated feed and 
subsequently experimentally challenged with Neoparamoeba spp. to determine fish 
toxicity and efficacy for preventing clinical signs of AGD. An efficient way to 
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examine initial in vivo efficacy and toxicity is through bath administration of the 
compound as it requires less resources and time. For AGD-affected Atlantic salmon 
and rainbow trout, it was identified that a 1 h seawater bath using a bithionol 
concentration of 1 mg L -1 exhibited no morbidity and reduced amoeba numbers and 
percent lesioned gill filaments from the seawater control. Bath administration of 
bithionol has been examined in numerous species infected with various parasites. 
Bithionol toxicity and efficacy is dependent upon host species and target parasite. 
With regard to salmonid parasites, such as Gyrodactylus sp. and khthyobodo 
necator, Santamarina etal. (1991) observed limited toxicity and complete in vitro 
efficacy against Gyrodactylus sp. in rainbow trout at 12.5 mg L -1 , with a minimum 
20 mg L -1 reported as efficacious in vivo. Tojo etal. (1994b) stated that bithionol 
was efficacious in vivo against I. necator in rainbow trout at 25 mg 1,1 for a 3 h bath 
on two consecutive days; higher concentrations exhibited some mortality. Bithionol 
was reported as efficacious against Neoparamoeba spp. at concentrations ranging 
from 1 to 35 mg L -1 ; however, at concentrations > 10 mg L i high percentage 
mortality was seen within 3 h for both Atlantic salmon and rainbow trout (Florent et 
al., 2007a). Finally, Madsen etal. (2000) determined that bithionol at 0.1 mg L -1 
was an effective treatment against trichodiniasis in European eels, Anguilla 
anguilla, but found bithionol to have a relatively narrow therapeutic index. 
Conversely, Buchmann et al. (1992) demonstrated that bithionol at 
0.1 mg 1_, -1 was not efficacious as a static bath against gill parasitic monogeneans, 
Pseudodactylogyrus sp. and concentrations > 1 mg 1_, -1 were toxic causing 100% 
mortality within 24 h in the European eel. Bithionol as a static bath has also been 
reported as effective in killing the ciliate Tetrahymena pyriformis at 60 mg L -1 , 
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whilst being non-toxic to the minnow golden shiner, Notemigonus crysoleucas 
(Griffin, 1989). Nonetheless, with the scale and intensity of salmonid farming 
occurring worldwide, a bithionol bath treatment would be impractical, as it is 
insoluble and would require a large amount of the compound to treat the bath water. 
On the other. hand, with the determination of toxicity to the target animal and its 
efficacy with respect to AGD it would be possible to incorporate bithionol in-feed 
and assess as an oral treatment for the control of AGD in Atlantic salmon. 
Although, Neoparamoeba spp. is an external parasite, similar to the treatment 
strategies for sea lice, the desired delivery method, from an industry perspective is 
an in-feed drug therapy. Reasons for this included the fact that in-feed treatment 
allows medication during adverse weather conditions and on exposed sites and 
reduces the chance of cross-infestation that may occur during the several days 
necessary to apply bath treatments to all cages on a site because an in-feed 
treatment permits simultaneous medication of all cages on a site. Hence the 
treatment of sea lice with an emamectin benzoate as a 0.2 % aquaculture pre-mix 
identified as SLICE ®  is ideal for famers compared to the bath treatments previously 
used (Stone et al., 1999). Furthermore, with the increasing need for the use of 
chemotherapeutants in aquaculture, it is very important to minimise the 
accumulation of chemicals in food for human consumption and the effect on the 
environment. Therefore, consideration for residues in the animal and accumulations 
and the effect on the environment must be taken when examining any compounds 
for use as treatments for disease in aquatic animals. 
- 126- 
Chapter Six 	 General Discussion 
Bithionol has been suggested as an oral medication due to its ability to provide 
easy administration and limited fish handling (Tojo and Santamarina, 1998a). 
Bithionol has a wide spread use in the treatment of numerous parasites in different 
hosts (El-Sayad, 1997). In cattle, bithionol sulphoxide was reported as effective at 
reducing Fasciola hepatica in the rumen when administered a single dose at 30 mg 
kg' for the first four weeks but numbers returned to pre treatment levels 20 weeks 
following treatment (Ueno etal., 1973). However, when administered as a single 
dose at 90 mg kg -1 bithionol sulphoxide reduced the natural rumen fluke infestation 
of cattle by 70% (Prasittirat etal., 1997). Bithionol was reported as effective in 
removing the worms Thysanosoma actinioides (Allen et al., 1962) and 
Hymenolepris nana (Maki and Yanagisawa, 1985) from sheep and mice, 
respectively. With examining aquatic animal health, bithionol at 40 g kg -I feed was 
offered for.10 days at 2% body weight (BW) per day to rainbow trout infected with 
Spironucleus salmonis (formerly Hexamita salmonis), Gyrodactylus sp. or I. 
necator and exhibited a reduction in parasite load. Bithionol eliminated 
approximately 80% of S. salmonis from rainbow trout whilst both Gyrodactylus sp. 
and I. necator infections were reduced from a high to low intensity (Tojo and 
Santamarina, 1998a; b; c). Kim and Choi (1998) reported bithionol administered in-
feed at 100-200 mg kg -I BW significantly reduced the number of monogeneans 
Microcotyle sebastis on the gills of cultured rock fish (Sebastes schlegeli), with a 20 
day feeding duration being most effective. Furthermore, bithionol was reported as 
efficacious delay and reducing clinical signs of AGD in Atlantic salmon when fed 
at 25 mg kg' feed either as a two week prophylactic treatment or a therapeutic 
treatment (Florent et al., 2007b). 
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Bithionol was successful in delaying and reducing clinical signs of AGD by 
approximately two weeks and even reducing the amoebae numbers by half would 
theoretically half the number of baths. Bithionol incorporated into feed would cost 
approximately $150 tonne -I (Sigma-Aldrich, 2006); if this successfully halved the 
bath numbers it has the potential to lessen the cost of treatment compared to 
freshwater. When examining the cost of bithionol and bithionol sulphoxide the 
price difference is considerable with bithionol eight times more expensive than 
bithionol sulphoxide, thus bithionol sulphoxide if as effective as bithionol is a 
significantly cheaper alternative. 
Bithionol has been identified as successful in stage I and II of the three-tiered 
approach mentioned above. In order to continue through to stage III involving field 
testing it would be advantageous to examine the pharmacology and residue levels of 
bithionol and its metabolites. Previous studies show that bithionol may work more 
effectively when high infection pressure is observed such as that in a laboratory trial 
as opposed to a low infection pressure seen typically in a farm situation (Chapter 5). 
Thus examining the efficacy of both bithionol and bithionol sulphoxide at lower 
infections pressure would be beneficial and aid in collating data to apply for an 
experimental license. 
The next phase of the research would include further investigation of bithionol as 
an in-feed treatment for AGD, incorporating examination of the effect of 
prophylactic and therapeutic treatments running experiments for a longer period of 
time to obtain more growth data, examining the effect of pulse feeding, or 
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conducting trials under more realistic field conditions with lower exposure doses 
and freshwater baths. Furthermore, sophisticated studies on the pharmacology of 
possible treatments are often lacking, owing in part to the limited knowledge about 
the biochemistry of parasite, which are more difficult to study in vitro than bacteria 
(Barrett-Connor, 1982). Therefore, in addition to studying clinical efficacy of 
bithionol as a treatment for AGD, pharmacokinetic examination is essential to 
establish correct dosage regimes and hence optimal drug usage (Samuelsen and 
Ervik, 1999; Haug and Hals, 2000; Stringer, 2001; Birkett, 2002; Katharios et al., 
2002). Pharmacokinetics describes the relationship between the dose and the 
unbound drug concentration at a drug receptor (otherwise known as the site of 
action), and the drug concentrations time course within the body (Birkett, 2002). 
Stringer (2001) relays pharmacokinetics as "the mathematical description of the rate 
and extent of uptake, distribution, and elimination of drugs in the body". 
The pharmacokinetics and bioavailability of a drug can be affected by several 
parameters including fish species, age, water temperature, salinity, and route of 
administration (Haug and Hals, 2000). Consequently knowledge of the 
pharmacokinetics and bioavailability of the drug used in the intended species is vital 
for correct application (Samuelsen and Ervik, 1999; Stringer, 2001; Birkett, 2002; 
Hansen et al., 2003). Favourable pharmacokinetic properties include good 
absorption after administration, high bioavailability, good tissue penetration and 
biotransformation (Stringer, 2001; Birkett, 2002; della Rocca etal., 2004). 
Although studies have been conducted on uptake, distribution and excretion in 
rodents a comparison with the results from rodents show that the toxicity of 
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antiparasitic drugs to aquatic organisms Islikely not well correlated to mammals 
(Yoshimura and Endoh, 2005). 
Neoparamoeba perurans has been confirmed a cosmopolitan protozoan parasite 
and, therefore, of significance to the global mariculture industry (Young etal., 
2008). Thus, confirmation of N. perurans in regions of significant finfish 
production indicates that AGD is of global significance to the mariculture industry 
and therefore the development of a cheaper alternative treatment of this disease has 
the potential to become a worldwide issue as opposed to a localised Tasmanian 
issue. 
6.1 	Conclusion 
This thesis evaluated the in vitro toxicity of bithionol and bithionol sulphoxide to 
Neoparamoeba spp. and determined that both bithionol and bithionol sulphoxide 
were toxic to Neoparamoeba spp. at concentrations ranging from 0.1 to 10 mg L -1 
over 72 .h; however, freshwater still remained the most toxic with complete 
mortality seen at 48 h. Following this, the toxicity of bithionol to Atlantic salmon 
and rainbow trout in fresh and seawater and the efficacy of bithionol as a 1 h 
seawater bath treatment for AGD were examined. It was determined that bithionol 
was toxic at and above 25 mg L -1 in freshwater and seawater for both Atlantic 
salmon and rainbow trout; whilst concentrations of 1, 5 and 10 mg L -1 produced an 
efficacy comparable to the currently used freshwater bath in Atlantic salmon. To 
follow on from Stage I to Stage II of drug testing, the efficacy of bithionol as an 
oral treatment for Atlantic salmon affected by AGD was examined. It was reported 
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that bithionol at 25 mg kg' feed, when fed as a two week prophylactic treatment for 
Neoparamoeba spp. exposure, delayed and reduced the intensity of AGD 
pathology. In order to enhance the knowledge of bithionol as an oral treatment for 
AGD the effects of prophylactic and therapeutic treatments were examined as well 
as the combination with a freshwater bath. It was identified that there was no 
difference in gross gill score or percent lesioned gill filaments when Atlantic 
salmon Were fed bithionol at 25 mg kg' feed prophylactically or therapeutically. 
When a freshwater bath was administered there was a proportional knock down 
suggesting that it may be advantageous to use bithionol as a combination therapy 
with the current freshwater mitigation to achieve the best results for reduction in 
clinical signs of AGD. 
The results of this thesis indicate that bithionol warrants, further investigation as a 
possible in-feed treatment for AGD in Atlantic salmon, especially as a combination 
therapy with the standard freshwater bath treatment. Also, examining the effect of 
pulse feeding or conducting trials under more realistic field conditions with lower 
exposure, doses and freshwater baths would be of interest. It would also be 
advantageous and necessary in order to develop the treatment further to examine the 
environmental effects along with the pharmacokinetics of bithionol. 
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Appendix I 
8 Appendix I 
8.1 	Trypsin-EDTA solution in Hanks Balanced Salts Contents and 
concentrations 
Trypsin 0.5 g L-1 
Ethylenediaminetetraacetic acid (EDTA) solution 0.2 g L -1 
Hanks Balance Salts (HBSS) Modified containing: 
KC1 0.4 gL -1 
KH2PO4 (anhyd) 0.06 g L -1 
NaHCO3 0.35 g 
NaC1 8.0 g 
Na2HPO4 (anhydrous) 0.04788 g L -1 
D-Glucose 1.0 g 
Phenol Red•Na 0.011 g 
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